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Abstract
Endoribonucleases have been implicated in post-transcriptional regulation in virtually 
all organisms. In vertebrates, the regulation of gene expression by mRNA turn-over is not 
well-understood as only few endoribonucleases have been purified and eventually cloned. 
Our lab has purified a novel endoribonuclease from rat livers that cleaves within the Coding 
Region Determinant (CRD) of the c-myc mRNA. c-Myc is a transcription factor belonging to 
the Myc family and it is over-expressed in many human cancers. mRNA stability involves an 
enhanced half-life of the mRNA in the cytoplasm and is one method leading to mRNA over­
expression. This type of over-expression has been observed in liver cancers, where the c-myc 
mRNA is stable compared to mRNA in the normal liver. The aim of this thesis was to 
determine the sequence and structure cleavage specificity of the endoribonuclease to nts 
1705-1792 of the c-myc CRD region. To further confirm the cleavage specificity of the 
endoribonuclease, nts 3018-3159 of the human (3-globin mRNA was used as a substrate in 
addition to a series of mutants encompassing the 1705-1792 c-myc CRD region. Prior to 
determination of preferential cleavage sites generated by the endonuclease, the in vitro 
secondary structures of the 1705-1792 c-myc CRD and the 3018-3159 (3-globin RNAs were 
determined using enzyme probes. The RNase probing data were then used as a constraint 
with the structure generated by the Mfold software program to obtain the experimental 
structure. The RNA substrates were then incubated with the endoribonuclease and the 
cleavage sites were identified. Results revealed that this endonuclease preferentially cleaves 
UA, CA and UG dinucleotides, regardless of strandedness and single-stranded CU 
dinucleotides. This study has the potential to enhance our knowledge on how the mammalian 
endoribonuclease may function in cells.
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Chapter 1 
Introduction
1.0 Overview of messenger RNA turn over
In the last two decades, mRNA decay has emerged as a major control point in gene 
expression in virtuaiiy aii organisms (Brewer, 2002; Decker and Parker, 1994; Dodson and 
Shapiro, 2002; Ross, 1995). The amount of protein that can be translated from mRNA is 
dependent upon the amount of time the mRNA persists in the cytoplasm (Cohurn and 
Mackie, 1999; Dodson and Shapiro, 2002).
Degradation hy mRNA turn-over is thought to play a critical role in four essential 
cellular processes: (i) the setting of the basal level of gene expression, (ii) elimination of 
aberrant mRNAs containing Premature Termination Codons (PTCs) or lacking codons, (iii) 
processing of pre-mRNAs, and (iv) defense against infectious double-stranded viral RNAs 
(Baker and Condon, 2004; Parker and Song, 2004).
The deadenylation-dependent and deadenylation-independent pathways are two 
models that have been suggested to regulate mRNA decay (Bremer et ah, 2003; Guhaniyogi 
and Brewer, 2001). The deadenylation-dependent pathway involves the shortening/removal 
of the poly(A) tail, followed by the removal of the 5’ cap, and lastly the exonueleolytie 
degradation by the 5’ to 3’ and/or the 3’ to 5’ exonucleases (Brewer, 1999; Brewer, 2002; 
Chernokalskaya et ah, 1997; Dodson and Shapiro, 2002; Guhaniyogi and Brewer, 2001; 
Tourriere et ah, 2001; Wennborg et ah, 1995) . In contrast, the deadenylation-independent 
pathway involves the cleavage of the mRNA without prior deadenylation (Baker and 
Condon, 2004; Brewer, 2002; Coller and Parker, 2004; Decker and Parker, 1994; Dodson 
and Shapiro, 2002; Schoenberg and Cunningham, 1999). It involves the rate-limiting step of
endonucleolytic cleavage within the body of the mRNA followed by exonueleolytie decay of 
the remaining message (Chernokalskaya et al., 1997; Dodson and Shapiro, 2002). The 
importance of this pathway stems from the fact that it is responsible for the fluctuations in the 
half-lives of many unstable mRNAs (Caruccio and Ross, 1994; Dodson and Shapiro, 2002; 
Ross, 1995).
The intrinsic half-lives of many mRNAs are dictated by both the cis determinants 
within the mRNA and the trans-acting factors that bind to them (Dodson and Shapiro, 2002; 
Guhaniyogi and Brewer, 2001; Wang and Kiledjian, 2000). Cis determinants can be located 
at any region within the mRNA, including the 3’UTR and Coding Region Determinants 
(CRD). The most common cis determinant, the AU-Rich Element (ARE), is found within the 
3’ UTR of mRNAs (Chen and Shyu, 1995; Ross, 1995) and has been implicated in mRNA 
instability, although there are few exceptions (Dodson and Shapiro, 2002). Examples of 
mRNAs containing destabilizing AREs in their 3’UTR are c-myc (Chen and Shyu, 1995), c- 
fo s  (Chen and Shyu, 1995), VEGE (Levy et al., 1998), and apolipoprotein II (Binder et al., 
1989). The coding regions of mRNAs have also been implicated in the control of mRNA 
stability. Examples include: c-myc (Yeilding et al., 1998), c-fos (Schiavi et al., 1992), and 13- 
tubulin (Bachurski et al., 1994) mRNAs. Secondary structural features are also thought to 
play a role in mRNA stability by inhibiting mRNA cleavage mediated by exoribonucleases 
and single-strand RNA-specific endoribonucleases (Coburn and Mackie, 1999).
1.0.1 Messenger RNA turn-over in prokaryotes
A model organism for studying mRNA decay is Escherichia coli, which has a typical 
mRNA half-life of 60-120 seconds (Coburn and Mackie, 1999). The poly(A) tail in bacteria 
functions to promote mRNA degradation (Coburn and Mackie, 1999; Steege, 2000) by
allowing exoribonucleases to access the 3’ stem-loops, which normally act to stabilize the 
mRNA (Coburn and Mackie, 1999; Steege, 2000). It is believed that with the presence of the 
single-stranded poly(A) tail docking site, exoribonucleases such as polynucleotide 
phosphorylase (PNPase) and RNase II can cleave the mRNA in a 3’ to 5’ direction 
(Callaghan et ak, 2003; Grunberg-Manago, 1999).
The short mRNA half-life observed in E.coli is mainly a consequence of the 
deadenylation-independent pathway, which recently has emerged as a major pathway for 
degradation of many bacterial mRNAs (Chernokalskaya et ak, 1997; Coburn and Mackie,
1999). Six major endoribonueleases that have been implicated in bacterial mRNA decay are 
RNase E, RNase G, RNase III, RNase P, MazF, and PemK (Kushner, 2002; Li and Altman, 
2003; Nicholson, 1999; Steege, 2000; Zhang et ak, 2004) (Table 1.1). RNase II, 
polynueleotide phosphorylase (PNPase), and oligoribonuclease have been specifically 
implicated in 3’ to 5’ exonueleolytie cleavage of bacterial mRNAs (Cheng and Deutscher, 
2005).
mRNA degradation in bacteria is thought to involve the initial rate-limiting step of 
endonucleolytic attack by RNase E (Coburn and Mackie, 1999). This is followed by 3’ to 5’ 
exonueleolytie attack by PNPase and RNase II (Baker and Mackie, 2003; Condon and 
Putzer, 2002; Grunberg-Manago, 1999; Kushner, 2002; Mishra, 2002; Nicholson, 1999; 
Rauhut and King, 1999; Steege, 2000). The mRNA decay process in bacteria has been 
further elucidated by the discovery of a multi-protein complex termed the degradosome. This 
complex is thought to be composed of RNase E (Coburn and Mackie, 1999), PNPase, RNA 
helicase, and several other ATP-dependent enzymes (Grunberg-Manago, 1999; Kushner, 
2002; Redko et ak, 2003).
Endoribonucleases that degrade mRNAs in E.coli 
RNase E
In the last 10 years, RNase E has emerged as the primary endonuclease responsible for the 
rate limiting step of bacterial mRNA degradation (Callaghan et ah, 2003; Coburn and 
Mackie, 1999; Kushner, 2002; Redko et ah, 2003; Wennborg et ah, 1995). It regulates the 
degradation, and thus the half-life, of many bacterial mRNAs, in addition to its role in 
processing ribosomal RNAs (Coburn and Mackie, 1999; Wennborg et ah, 1995). Targets of 
RNase E include 9S RNA, the 5’UTR of ompA RNA, and the 5’ UTR of phage T4 gene 32 
mRNA (Ghora and Apirion, 1978; Lundberg et ah, 1995; Lundberg et ah, 1990; Mudd et ah, 
1988). RNase E was found to cleave single-stranded RNA regions near the 5 '-terminus 
region, in close proximity to the translation initiation site (Nicholson, 1999). It is also 
believed that RNase E cleaves upstream of the stabilizing 5’ secondary structural features, 
thereby generating fragments that are then susceptible for degradation by 3’ to 5’ 
exonucleases (Baker and Mackie, 2003; Grunberg-Manago, 1999). Furthermore, it has 
recently been shown that RNase E preferentially cleaves 5’ to AU dinucleotides in A/U rich 
regions (Coburn and Mackie, 1999). An experiment was performed to investigate the 
structural requirement of RNase E, in vitro, to its 9S and 20S RNA targets by generating 
several structural mutants (Cormack and Mackie, 1992; Mackie and Genereaux, 1993). The 
conclusion was that RNase E cleaves its target sequences only when present in single­
stranded domains.
RNase G
RNase G has been implicated in the maturation of the 5 'end of 16S RNA, rRNA 
processing and M l RNA processing (Jiang and Belasco, 2004; Wachi et ah, 1999). This
endonuclease comprises 489 amino acid residues and shares extensive homology to the 
endonucleolytic domain (amino half) of RNase E (Jiang and Belasco, 2004). Therefore, it is 
not too surprising that both RNase E and RNase G have similar cleavage specificity as they 
both prefer to cleave 5 ’ to AU dinucleotides (in AU-rich regions) only when present in 
single-stranded conformations (Hua et al., 1993; Jiang and Belasco, 2004; Tock et al., 2000). 
RNase III
RNase III has also been implicated in the rate-limiting step of endonucleolytic degradation 
of many bacterial mRNAs, although not to the same degree as RNase E (Condon and Putzer,
2002). It has little RNA sequence specificity (Condon and Putzer, 2002; Lamontagne et al., 
2004) and it has an absolute requirement for double-stranded regions, as it was found to be 
incapable of cleaving single-stranded regions in vitro (Robertson et al., 1968). RNase III was 
also found to be capable of autoregulating itself by cleaving its own stem-loop structure 
(Condon and Putzer, 2002).
RNase P
RNase P is a ribonucleoprotein that is responsible for the cleavage of precursor tRNA 
molecules to generate mature tRNA 5’ ends (Altman et al., 1993; Mishra, 2002; Nicholson,
1999). It consists of a 377 nt RNA subunit encoded by mpB  gene and ~ 130 kDa protein 
subunit encoded by the rnpA gene (Altman et al., 1993; Nicholson, 1999). In addition to its 
role in tRNA maturation, it is also likely to play a role in bacterial mRNA turn-over as it was 
found to cleave polycistronic mRNAs in vitro such as tryptophanase (tnaA). RNase P was 
able to cleave between the single-stranded U47 and 048 within the tnaA operon RNA (Li 
and Altman, 2003). It has been hypothesized that the products generated by RNase P are
subsequently degraded by RNase E, followed by 3’ to 5’ degradation by PNPase (Li and 
Altman, 2003).
MazF
MazF is a dimerie endoribonuelease that preferentially cleaves RNA 3’ to the first 
adenosine residue in ACA sequences only in single-stranded conformations (Zhang et ah, 
2005; Zhang et al., 2003). However in another study, this endoribonuclease showed different 
sequence specificity and it was found to cleave 3’ to N residues within NAC sequences 
(where N = an A or U) in single-stranded conformations (Munoz-Gomez et ah, 2004).
PemK
Another endonuclease implicated in E.coli mRNA decay is PemK, which functions to 
block protein synthesis (Zhang et ah, 2004). It preferentially cleaves its target mRNA 5’or 3’ 
to the adenosine residue of the UAH sequence, only when present in single-stranded regions 
(Zhang et al., 2004).
Table 1.1. Bacterial endonucleases and their cleavage sites.
Name of 
endonuclease
Cleavage site RNA Structure 
specificity of the 
endonuclease
References
RNase E 5’ to AU dinueleotides in 
AU rich regions (upstream 
of stem-loops)
Single-stranded (Coburn and 
Mackie, 1999)
RNase G Similar to RNase E Single-stranded (Waehi et ak, 
1999)
RNase III Little sequence specificity Double-stranded (Lamontagne 
and Elela, 2004)
RNase P Between U47 and G48 in 
the tna operon
Single-stranded (Li and Altman, 
2003)
MazE 3’ to the first adenosine 
residue in ACA sequenees 
or 3’ to N residues in NAC 
sequenees (N = A or U).
Single-stranded (Munoz-Gomez 
et al., 2004)
PemK 5’ or 3’ to the adenosine 
residue in UAH sequences 
(H= C, A, or U)
Single-stranded (Zhang et al., 
2004)
1.0.2 Messenger RNA turn-over in lower eukaryotes (yeast)
The deadenylation-dependent pathway is best defined in yeast and it appears to be the 
major mechanism for the regulating of mRNA decay in yeast (Brewer, 1999; Chernokalskaya 
et al., 1997; Coller and Parker, 2004; Decker and Parker, 1994; Decker and Parker, 2002; 
Guhaniyogi and Brewer, 2001; Wang and Kiledjian, 2000). This pathway begins with 
deadenylation of the mRNA by poly(A) nuclease (PAN), followed by decapping of the 
mRNA by DCPl (Bremer et ak, 2003; Decker and Parker, 2002; Dodson and Shapiro, 2002; 
Liu et ak, 2002; Rodgers et ak, 2002; Uchida et ak, 2004). The deadenylated and decapped 
mRNA is then degraded rapidly by the 5’ to 3’ exonuclease XRNl (Beelman and Parker, 
1995; Bremer et ak, 2003; Brewer, 2002; Cunningham et ak, 2001; Decker and Parker, 2002; 
Dodson and Shapiro, 2002; Rodgers et ak, 2002; Wilusz et ak, 2001). A 3’ to 5’ 
exonueleolytie pathway is also observed in yeast. This pathway also depends on the 
deadenylation and decapping of the mRNA and involves a heteropentameric protein complex 
(namely, the exosome) consisting of several exonucleases (Brewer, 1999; Brewer, 2002; 
Decker and Parker, 1994). Although less prominent, the deadenylation-independent mRNA 
decay pathway is also likely to occur in yeast (Bremer et ak, 2003). Endonucleases that have 
been identified to degrade mRNA in yeast are R ntlp (Elela et ak, 1996) and RNase MRP 
(Cai et ak, 2002) (Table 1.2).
Rntlp
Rntlp has been implicated in yeast pre-mRNA processing by cleaving double-stranded 
regions found within unspliced pre-mRNAs and lariat introns (Danin-Kreiselman et ak,
2003). This creates entry sites for the XRNl or exosomes, which degrade the mRNA body 
(Danin-Kreiselman et ak, 2003). Unlike the sequence non-specific bacterial RNase III, Rntlp
was found to be sequence-specific as it cleaves double-stranded regions only near 5’ NGNN 
3’ tetra-loops (Lamontagne and Elela, 2004).
RNase MRP
RNase MRP (Mitochondrial RNA Processing) is a ribonucleoprotein that is thought to 
possess one catalytic RNA subunit and ten protein subunits (Schmitt and Clayton, 1992). 
This endonuclease has been implicated in mitochondrial rRNA processing and CLB2 (cyclin 
B gene) mRNA decay (Gill et ah, 2004). RNase MRP was found to cleave CLB2 mRNA in 
the 5’ UTR at several yet undefined sites in vitro, followed by a rapid XRNl-dependent 5’ to 
3’ exonueleolytie degradation (Gill et ah, 2004).
A summary of the eleavage sites and strueture specificity of the two yeast endonucleases 
is shown in Table 1.2. With the purifieation of these two novel endonucleases, it is becoming 
clear that endonucleases play an important role in yeast mRNA decay.
Name of 
endonuclease
Cleavage site RNA Structure 
specificity of the 
endonuclease
References
Rntlp In proximity to 5’ NGNN 
3’ tetra-loops (N= any 
nucleotide)
Double-stranded (Lamontagne 
and Elela, 2004)
RNase MRP 5’ UTR of CLB2 mRNA Not known (Gill et ah, 2004)
Other means of post-transcriptional regulation of mRNA in yeast includes RNA- 
interference (RNAi) (Lingel and Izaurralde, 2004; Vermeulen et ah, 2005), Non-sense 
Mediated Decay (NMD) and Non-Stop mediated Decay (NSD) (Baker and Condon, 2004). 
RNA interference involves the reliance on two main endoribonueleases, which include the 
Dicer and Argonaute2 proteins. The structure and sequence specificity of these proteins to 
RNAs will be discussed in section 1.2.1.
Non-sense mediated decay involves the removal of mRNAs containing a premature 
termination codon (PTC) (Culbertson and Neeno-Eckwall, 2005; Huang et al., 2004). This 
pathway involves deadenylation-independent decapping, followed by 5’ to 3’ degradation of 
the mRNA, which occurs due to the recognition of PTCs (Cougot et ah, 2004; Gatfield and 
Izaurralde, 2004; Stevens et ah, 2002). Although a minor pathway, a 3’ to 5’ exonueleolytie 
degradation of mRNAs containing PTCs is also thought to occur by exosome degradation 
(Butler, 2002; Cougot et ah, 2004; Gatfield and Izaurralde, 2004; Mitchell and Tollervey,
2000). Exosomes have also been implicated in NSD, which involves the recognition and 
removal of mRNAs lacking a proper stop codon (Cougot et ah, 2004).
1.1 The cellular-mjc {c-myc) gene
c-myc is a member of the myc gene family, which includes N-myc, h-myc, B-myc, and 
R-myc (Hodgson SV, 1993). All of these members are characterized by their function as 
transcription factors (Facchini and Penn, 1998; Gardner L, 2002; Hodgson SV, 1993; 
McAllister RM, 1993; Supino et ah, 2001). c-myc, however, was found to be the only 
transcription factor involved in the normal cell growth. It is overexpressed in 80% of breast 
cancers, 70% of colon cancers, 90% of gynecological cancers, and 50% of hepatocellular 
carcinomas and many hematological tumors (Gardner L, 2002). Based on these findings, it is 
estimated that c-myc overexpression contributes to the death of approximately 100,000 U.S 
cancer patients per year which represents 14.3% of all cancer deaths (Gardner L, 2002). 
These findings underscore the importance of studying this proto-oncogene.
1.1.1 The c-Myc protein and its role in the normal cell and in cancer 
c-mvc structure and function
The c-Myc protein consists of an N-terminal transactivating domain, a nuclear localization 
signal in the middle domain, and a C-terminal DNA-binding domain (Facchini and Penn, 
1998; Gardner L, 2002). The C-terminal domain contains the dimerization motif, which is 
required for the formation of a heterodimer with a protein called Myc-associated factor X or 
Max (Facchini and Penn, 1998; Gardner L, 2002). Such dimerization has been shown to be a 
prerequisite for the function of c-Myc as a transcription factor (Sommer et al., 1998). In 
addition to Max, c-Myc can be regulated by other proteins which can either induce or inhibit 
its activity (Facchini and Penn, 1998; Gardner L, 2002). As a transcription factor, it can act 
as an activator or repressor to regulate a variety of genes such as those involved in gene 
expression and cell-cycle control (Facchini and Penn, 1998; Gardner L, 2002).
Over the last decade, great progress has been made in understanding the role of c- 
Myc in both normal and cancer cells (Gardner L, 2002). This intense effort has revealed that 
c-Myc is implicated in such cellular processes as the cell-cycle, apoptosis, and differentiation 
(Facchini et al., 1997; Facchini and Penn, 1998; Gardner L, 2002; Henriksson and Luscher, 
1996; Levens, 2003; McEwan et al., 1996). In the normal cell, c-myc is tightly regulated. 
This regulation is dependent on external signals such as growth factors and extracellular 
matrix contacts, as well as internal signals stemming from the cell-cycle (Gardner L, 2002). 
Normally, the resting cell has little c-myc expression, however, upon stimulation by growth 
faetors, c-myc expression is induced and a burst of c-myc mRNA and protein can be observed 
(Campisi et al., 1984; Kelly et al., 1983; Moore et al., 1987). This expression declines, but
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remains constant throughout the cell-cycle until the generation of the resultant resting 
daughter cells (Camplsl et ah, 1984; Kelly et ah, 1983; Moore et ah, 1987).
Regulation of c-m\c gene expression
In order for c-myc to appropriately respond to Internal and external signals (hence 
promoting normal cellular growth), Its activity must be regulated rapidly and efficiently. This 
regulation Is achieved by a wide variety of Intricate mechanisms. These mechanisms Include 
regulation at the transcriptional, post-transcrlptlonal, and post-translatlonal levels (Facchini 
and Penn, 1998). Transcriptional level regulation Is thought to be mediated by environmental 
signals activating the signal transduction pathway, which then exert their effects on the 
several regulatory elements of the c-myc gene (Facchini and Penn, 1998). Transcription of c- 
myc can also be regulated by negative feedback autoregulation as demonstrated In in vivo 
studies (Grlgnanl et ah, 1990; Penn et ah, 1990). This type of regulation Involves the binding 
of the Myc-Max heterodimer to the regulatory elements leading to the suppression of c-myc 
gene transcription (Facchini et ah, 1997; Facchini and Penn, 1998). Regulation at the post- 
transcrlptlonal level has been Intensely studied recently and may Involve the activity of 
exonucleases and/or endonucleases (Brewer, 2002; Guhaniyogi and Brewer, 2001). This type 
of regulation will be discussed In section 1.1.2. Finally, post-translatlonal regulation Involves 
protein phosphorylation and the proteln-proteln Interactions (Facchini and Penn, 1998).
In contrast to the tight regulation observed In normal cells, c-Myc-Induced cancers 
exhibit abnormal or, more specifically, constitutive expression of c-myc (Facchini et ah, 
1997; Facchini and Penn, 1998). This results from the breakdown of one or more of the 
regulatory mechanisms described earlier (Facchini et ah, 1994). As a consequence, the 
function of c-Myc Is exaggerated, leading to a constant progression through the cell-cycle
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and therefore eontributing to the conversion of normal cells into cancer cells (Facchini et ah, 
1997; Facchini and Penn, 1998). Although the oncogenic activity of c-Myc, alone, is a strong 
promoter of cellular proliferation, additional cooperating oncogenic mutations are required 
for the transformation to a malignant phenotype, hence, supporting the characteristic multi- 
step process of carcinogenesis (Facchini and Penn, 1998; Tannoek IF, 1998).
The activation of c-myc, or its conversion from a proto-oncogene to an oncogene, 
occurs via several gross genetic aberrations including chromosomal 
translocation/rearrangement, gene amplification, proviral insertion, and mRNA stabilization 
(Marcu et ah, 1992; Spencer and Groudine, 1991). The best known example to illustrate the 
chromosomal translocation aberration involves Burkitt’s lymphoma. This type of cancer 
involves the juxtapositioning of the c-myc locus near the regulatory region of the IgG heavy 
chain in B-cells (Spencer and Groudine, 1991). The IgG regulatory region is highly active in 
lymphocytes as it is constantly responding to antigens and consequently producing antibodies 
(Facchini et ak, 1997; Gardner L, 2002). The result is a 10-20 fold overexpression of the c- 
myc gene (Facchini and Penn, 1998).
Gene amplification involves an increase in the copy number of c-myc, resulting in an 
exaggeration of c-Myc’s activity (Gardner L, 2002). The first proto-oneogene observed to be 
amplified was in fact the c-myc amplification in patients with myelocytic leukemia. These 
cancer cells contained 8-30 copies of the c-myc gene (Facchini and Penn, 1998). Another 
example of gene amplification includes SCLC (small cell lung cancer) cell lines, which 
contain 50 copies of the c-myc gene per cell (Catapano et ak, 2000; Gardner L, 2002).
c-myc induced cancers due to retroviral insertion involves the insertion of regulatory 
regions near c-myc, leading to its activation (Tannoek IF, 1998). It may also involve the
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insertion of retroviral sequences in the c-myc coding region, leading to the formation of an 
abnormal and constitutive c-myc protein (Tannoek IF, 1998). The role of mRNA stabilization 
in the overexpression of c-myc mRNA in human cancers is currently under investigation. It is 
thought to involve protein shielding of destabilizing regions from endonucleases that infer 
mRNA instability. An example includes the stability of c-myc mRNA in liver cancer (Lee et 
al., 1998a).
1.1.2 Pathways of c-myc mRNA degradation and in vivo evidence for post- 
transcriptional regulation of c-myc mRNA
One pathway in which the short half-life of c-myc mRNA is regulated includes the 
deadenylation-dependent pathway (Brewer, 1998; Brewer, 1999). This pathway has been 
shown to occur in vivo, where a sequential decay pathway involving deadenylation, followed 
by 3’ to 5’ degradation of the mRNA was observed (Brewer, 1998; Brewer, 1999) in the AU- 
rich element within the 3’ UTR (Bremer et al., 2003; Brewer, 1999; Doyle et al., 2000). A 3’ 
to 5’ exonuclease that cleaves c-myc mRNA, in vitro, within an AU-rich region of the 3’UTR 
has been purified (Brewer and Ross, 1988). However, it is still not known if this exonuclease 
is the one observed in vivo (Brewer, 1999).
In addition to the 3’ to 5’ exonueleolytie cleavage, c-myc mRNA can be degraded 
endonucleolytically by the RasGAP-associated G3BP (Tourriere et ak, 2001) , an RNase E- 
like endonuclease (Wennborg et al., 1995), and -39  kDa endonuclease (Lee et al., 1998b) 
(see section 1.2.1). Both the RasGap-associated G3BP and the RNase E-like endonucleases 
are associated with ribosomes and cleave AU-rich elements within the 3 -UTR of c-myc 
mRNA in vitro (Tourriere et ak, 2001; Wennborg et ak, 1995).
In addition to the 3 -UTR, c-myc mRNA can be cleaved endonucleolytically within 
its coding region (Doyle et ak, 2000; Guhaniyogi and Brewer, 2001; Hanson and
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Schoenberg, 2001; Pistol et al., 1996). The implicated endonuclease is a -39 kDa protein 
which requires magnesium for activity (Lee et al., 1998b). Studies done in vitro revealed that 
this endonuclease cleaves within the coding region determinant (CRD), which encompasses 
the last 182 nucleotides of the protein coding sequence (Figure 1.1). Although in vivo 
cleavage of the CRD by this endonuclease is not yet known, there is evidence implicating the 
CRD in c-myc mRNA stability. Upon insertion of the c-myc CRD into the coding region of 
the stable globin mRNA, the globin mRNA was rendered unstable in cells (Herrick and Ross, 
1994). Furthermore, deletion of both the 5’ and 3’ UTRs of c-myc mRNA did not alter the 
half-life of the mRNA in cells, supporting the involvement of the coding region in c-myc 
mRNA instability (Bonnieu et al., 1990; Lachman et al., 1986). Finally, post-transcriptional 
down-regulation of c-myc mRNA, upon the conversion of myoblasts to myotubes, required 
the CRD (Kren et al., 1996; Lee et al., 1998b; Wisdom and Lee, 1990; Wisdom and Lee, 
1991; Yeilding et al., 1998). Down-regulation of the mRNA does not occur upon deletion of 
the CRD (Wisdom and Lee, 1990; Yeilding et al., 1998). This evidence, along with the 
finding that c-myc mRNA can be degraded endonucleolytically in cells, as evidenced by the 
presence of CRD decay products, (Hanson and Schoenberg, 2001; Pistol et al., 1996) 
highlights the importance of finding the endonuclease that can cleave within the CRD of the 
c-myc mRNA.
5.UTR Coding Region 3’-UTR
c-mjfc mRNA CRD
Figure 1.1 A schematic representation of the c-myc mRNA. The coding region determinant 
(CRD) is implicated in the regulation of c-myc mRNA turnover by the 39 kDa endonuclease.
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The CRD is also the binding site for an RNA-binding protein. Based on in vitro 
experiments, a protein that binds with considerable specificity to sequences located in the 
CRD RNA has been identified and is termed the CRD-binding protein or CRD-BP (Bernstein 
et a l, 1992; Lee et a l, 1998b; Prokipcak et a l, 1994). The binding of CRD-BP to the CRD 
region indicates a potential role for this protein in regulating c-myc mRNA decay. CRD-BP 
is thought to protect the CRD of c-myc mRNA from endonucleolytic attack (Bernstein et a l, 
1992; Doyle et a l , 2000; Lee et a l, 1998b; Prokipcak et a l, 1994). However, this hypothesis 
is yet to be tested either in vitro or in vivo. An antisense oligonucleotide targeting the 1763- 
1777 CRD region (5’ AGCCACAGCAUACAU 3’) was found to be the most effective in 
inhibiting c-myc expression, suggesting that this region is an important binding site for CRD- 
BP (Coulis et a l, 2000).
1.2 Overview of messenger RNA turn-over in higher eukaryotes
The deadenylation-dependent and deadenylation-independent pathways have been 
demonstrated in mammals. However, the details by which most mammalian mRNAs are 
degraded are not well-understood (Brewer, 1999; Brewer, 2002; Ross, 1995). It has been 
hypothesized that many mammalian mRNAs are degraded by a deadenylation-dependent 
mechanism in vivo (Dodson and Shapiro, 2002; Ross, 1995; Wilusz et a l , 2001). This 
involves the initial rate-limiting step of a 3’ to 5’ exonucleolytic removal of the poly(A) tail 
by poly(A) ribonucleases. (Cunningham et a l, 2001; Decker and Parker, 2002; Dodson and 
Shapiro, 2002; Uchida et a l, 2004). Recently, a human cytoplasmic poly(A) ribonuclease 
deadenylase was identified and it was termed human PABP-dependent poly(A) nuclease 
(hPAN) (Uchida et a l, 2004). It is a magnesium-dependent 3’ to 5’ exonuclease, that is 
stimulated to degrade the mRNA by binding to the Poly(A) binding protein (PABP) in vivo
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(Uchida et al., 2004). Another deadenlyase was found in vertebrates and it was termed PARN 
(^oiyA ribonuclease) (Korner and Wahle, 1997). Unlike hPAN, PARN is stimulated to 
cleave the mRNA by binding to the 5’ cap structure (Decker and Parker, 2002; Korner and 
Wahle, 1997). After deadenylation, subsequent decay steps, which involve the mRNA body, 
generally occur so quickly that decay intermediates are not detected, hence, hampering 
further analysis of the decay pathways (Brewer, 1999). Nonetheless, recent evidence 
implicates mammalian mRNA involvement in the 5’ to 3’ and 3’ to 5’ exonucleolytic decay 
pathways.
Evidence for 5 ’ to 3’ exonucleolytic degradation
The implication that mammalian mRNAs can be degraded in a 5 ’ to 3’ deadenylation- 
dependent pathway similar to the one in yeast, is based on three main findings. The first 
finding includes the identification of the poly(A) ribonucleases mentioned previously. The 
other two findings involve the discovery of XRNl and DCPl mammalian homologues 
(Bashkirov et al., 1997; Cunningham et al., 2001; Dodson and Shapiro, 2002; Ross, 1995). 
The human decapping enzyme, DCPl, and the 5’ to 3’ exonuclease, X RNl, were found to 
co-localize in cytoplasmic foci termed, GW (because they contain a protein that is highly 
abundant with glycine and tryptophan amino acids) bodies, which represent sites of active 
mRNA degradation (Cougot et al., 2004).
Evidence for 3’ to 5 ’ exonucleolytic degradation
In addition to the 5’ to 3’ deadenylation-dependent pathway, a 3’ to 5’ deadenylation- 
dependent pathway is also thought to regulate mammalian mRNA decay (Coburn and 
Mackie, 1999; Cunningham et al., 2001; Hanson and Schoenberg, 2001; Liu et al., 2002). 
This is evident from two observations, which include the discovery of an exosome
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homologue in HeLa cell lines (Mitchell et al., 1997) and the 3’ to 5’ exonucleolytic decay of 
the H4 human histone mRNA (Ross et ah, 1986). The mammalian exosome has been purified 
and its composition appears to be similar to its yeast counterpart (Chen et al., 2001).
Evidence for endonucleolytic degradation
The deadenylation-independent pathway is also thought to regulate mammalian mRNA 
turn-over (Cunningham et al., 2001; Grunberg-Manago, 1999; Hanson and Schoenberg,
2001). This is determined mainly through the identification of endonucleolytic cleavage sites 
in many mammalian mRNAs (Caruccio and Ross, 1994; Dodson and Shapiro, 2002). The 
identity and properties of mammalian endonucleases that target specific mRNAs for decay 
under normal physiological condition remain elusive, as only few mammalian mRNA 
endonucleases have been purified and subsequently characterized (Table 1.3) (Caruccio and 
Ross, 1994; Claverie-Martin et al., 1997; Dodson and Shapiro, 2002). The search for 
mammalian endonucleases is essential for understanding the post-transcriptional control of 
mammalian gene expression (Brewer and Ross, 1988; Wennborg et al., 1995). 
Endoribonucleolytic digestion is responsible for the decay of several vertebrate mRNAs 
including those for albumin (Cunningham et al., 2001), human transferrin receptor (Binder et 
al., 1994), insulin-like growth factor II (Meinsma et al., 1992), chicken apolipoprotein II 
(Binder et al., 1989), human a-globin  (Wang and Kiledjian, 2000), human P-globin (Stevens 
et al., 2002), human c-myc (Lee et al., 1998b), Xenopus vitellogenin (Cunningham et al.,
2000), p27^^^’ (Zhao et al., 2000) and interleukin II (Hua et al., 1993). The cleavage 
specificity of the endonucleases for these mRNAs is discussed in section 1.2.1.
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Stress-regulated pathways for mRNA degradation
Post-transcriptional regulation also plays a role in mammalian cellular processes such 
as RNAi, NMD, and NSD. Similar to yeast, RNAi in mammals relies on the Dicer and 
Argonaute! proteins (Liu et al., 2004; Vermeulen et al., 2005) (see section 1.2.1). The NMD 
pathway in mammals is also thought to be similar to the one in yeast and is believed to occur 
via the 5’ to 3’ (involving decapping and 5’ to 3’ exonucleolytic digestion) or the 3’ to 5’ 
(deadenylation followed by 3’ to 5’ degradation) degradation pathways (Chen and Shyu, 
2003; Lejeune et al., 2003). The exonucleolytic enzymes involved in the NMD pathway are 
thought to be the same enzymes responsible for the degradation of normal mRNAs (XRN1 
and the exosome) (Lejeune et al., 2003). In contrast, the NMD pathway in Drosophila was 
found to rely on endonucleolytic cleavage near the premature termination codon of the 
aberrant mRNA rather than the deadenylation-dependant pathway (Gatfield and Izaurralde,
2004). This pathway is thought to involve the rate-limiting step of endonucleolytic cleavage, 
followed by 5’ to 3’ degradation of the 3’ fragment by XRNl and 3’ to 5’ degradation of the 
5’ fragment by the exosome (Gatfield and Izaurralde, 2004). The endonuclease responsible 
for mediating the NMD pathway in Drosophila has yet to be identified.
Mammalian mRNAs containing non-stop codons are degraded by the NSD pathway 
(Frischmeyer et al., 2002; van Hoof et al., 2002). This pathway is thought to be mediated by 
deadenylation, followed by 3’ to 5’ degradation of the mRNA body by the exosome 
(Frischmeyer et al., 2002; van Hoof et al., 2002). 
itiRNA-binding proteins
mRNA-binding proteins are also thought to be implicated in mammalian post- 
transcriptional mRNA decay by binding to cA-elements within the mRNA. Proteins, such as
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tristetraprolin (Lai et al., 2002), KSRP (Chen et al., 2001), TIA -1  (Pieeyk et al., 2000) and 
TIAR (Pieeyk et al., 2000; Wilusz et al., 2001), have been implieated in mRNA 
destabilization. The destabilizing function is thought to mediated through the recruitment of 
an exosome that degrades the mRNA in a 3’ to 5’ direction (Brewer, 2002). In contrast, 
mRNA-binding proteins such as HuC (Ma et al., 1997), HuD (Manohar et al., 2002), HuR 
(Ma et al., 1996), CRD-BP (Bernstein et al., 1992), a-CP (Ji et al., 2003; Kong et al., 2003), 
vigilin (Cunningham et al., 2000), and La antigen (Heise et al., 2001) are thought to mediate 
mRNA stabilization by shielding the mRNA from endonucleolytic attack (Brewer, 2002). 
The AUFl mRNA-binding protein is thought to mediate both mRNA stabilization and 
destabilization, depending on eell-types (Loflin et ah, 1999; Xu et ah, 2001).
1.2.1 Endoribonucleases that degrade mRNAs in vertebrates
Although less well-studied, endonuclease-mediated mRNA decay appears to be more 
common than previously expected. A summary of the characterized endonucleases and their 
cleavage sites is shown in Table 1.3. The following is a more detailed insight into the 
vertebrate endonucleases that have been characterized.
PMR-1
Polysomal Ribonuclease 1 (PMR-1) is a member of the peroxidase gene family and is the 
most extensively studied mRNA endoribonuclease in vertebrates (Cunningham et ah, 2001; 
Stevens et ah, 2002; Yang and Schoenberg, 2004). It is a 62 kDa liver polysomal 
endoribonuclease that is activated by estrogen to degrade polysomal-associated serum protein 
mRNAs such albumin mRNA (Yang and Schoenberg, 2004). Degradation occurs in the 
3’UTR of albumin mRNA upon estrogen induction of Xenopus hepatoeytes in vivo 
(Cunningham et ah, 2001; Stevens et ah, 2002; Yang and Schoenberg, 2004). PMR-1 is also
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thought to degrade vitellogenin mRNA in the 3’ UTR in vitro and in vivo (Cunningham et al.,
2000). Upon estrogen stimulation, however, the 3’UTR of vitellogenin mRNA is thought to 
be shielded from PMR-1-indueed degradation by the RNA-binding protein, vigilin 
(Cunningham et al., 2000; Stevens et al., 2002). PMR-1 preferentially eleaves UG 
dinucleotides (3’ to the uridine residue) present in ApyrUGA elements both in vitro and in 
vivo (where pyr can be either a C or U residue) (Bremer et al., 2003; Hanson and 
Schoenberg, 2001) in single-stranded regions only (Hanson and Schoenberg, 2001). PMR-1, 
however, is not thought of as a restriction endonuclease in that non-consensus sequences can 
also be cleaved (Hanson and Schoenberg, 2001). The N-terminal domain of PMR-1 is 
thought to be important for endonucleolytic degradation of substrates (Yang and Schoenberg, 
2004). In particular, it is believed that one or more tyrosines in the N-terminal domain play a 
role in the endonucleolytic degradation of albumin mRNA (Yang and Schoenberg, 2004).
A -26 kDa endonuclease that cleaves Hepatitis B viral RNA
This endonuclease is a 26 kDa cytokine-activated endoribonuclease that was purified from 
liver nuclear extracts (Heise et al., 2001). Upon HBV infection, cytokines such as IFN-yand 
TNF-a become up-regulated and an enhanced activity of the endoribonuclease is observed 
(Heise et al., 2001). Such activation may be due to translational modification, or the 
inactivation of an inhibitor (Heise et al., 2001). Up-regulation of the cytokines also leads to 
the decrease of the RNA binding protein, Ua antigen, which may act to sterically hinder the 
endonuclease from accessing the cleavage site (Heise et al., 2001). Upon incubation of the 
endonuclease with a viral RNA transcript encompassing nucleotides 1243-1333, 
it preferentially cleaved 3’ to the two adenosine residues in the 5 -CCAUACU-3’ motif 
located 5’ to a stem-loop structure, which is also binding site for the La antigen (Heise et al..
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2001). Despite this knowledge, it is currently not known whether surrounding sequences or 
structural features play a role in the recognition of the site cleaved by the endoribonuclease, 
whose identity remains unknown (Heise et al., 2001).
RNase L
RNase L is an endonuclease that also relies on hormonal activation. It is 740 kDa 
endoribonuclease that targets viral RNAs for degradation (Silverman, 2003) and is believed 
to play a role in defense against viral RNA upon interferon activation (Li et al., 2000). RNase 
L preferentially cleaves at single-stranded UA and UU dinucleotides (Han et al., 2004; 
Mishra, 2002), causing the mammalian infected cells to undergo apoptosis (Pandey and Rath, 
2004). The endonucleolytic domain of RNase L is found in the C-terminal region (Silverman,
2003). This region is also thought to be a kinase-like domain, based on sequence homology 
studies (Mishra, 2002; Silverman, 2003).
RasGap-associated G3BP
RasGAP-associated G3BP is a 52 kDa endonuclease that was found to cleave within the 
3’UTR of c-myc mRNA in vitro (Barnes et al., 2002; Guitard et al., 2001; Tourriere et al.,
2001). This endonuclease is unique in that it requires phosphorylation (Tourriere et al., 2001) 
and phosphorylation-dependent protein-protein interaction to regulate its activity in c-myc 
mRNA degradation (Irvine et al., 2004). G3BP prefers to cleave 3’ to cytidine residues in CA 
dinucleotides only when present in single-stranded regions (Tourriere et al., 2001). Recent 
evidence indicate the importance of G3BP in vivo, as inactivation of the G3BP-encoding 
gene in animal models led to embryonic lethality and growth retardation (Zekri et al., 2005). 
The endonucleolytic domain of G3BP has yet to be identified as it has no sequence 
homology with any other known proteins.
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A ~65 kDa RNase E-like endonuclease that cleaves c-myc mRNA
Another enzyme implieated in c-myc mRNA cleavage includes the RNase E-like 
endonuclease. This enzyme is 65 kDa in size and was purified from different human cell- 
lines (Wennborg et ah, 1995). Similar to bacterial RNase E, it eleaves E.coli 98 RNA and 
outer membrane protein RNA (ompA). It preferentially eleaves 3’ to the 2"^ U residue in the 
5’AUUUA 3’ destabilizing motif present in the 3’ UTR (Wennborg et ah, 1995). This 
enzyme was also found to cleave c-myc mRNA within the 5’ AUUUA 3’ motif that is present 
in the 3’ UTR (Wennborg et ah, 1995). This endonuclease, whose identity is yet unknown, 
was found to cross-react with antibodies against bacterial RNase E (Wennborg et al., 1995).
A ~39 kDa endonuclease that cleaves c-mvc mRNA
A -39 kDa liver polysomal endonuclease that was purified from rat livers, has been found 
to cleave within the CRD of c-myc mRNA in vitro (Lee et al., 1998b). This enzyme is 
magnesium-dependent and is not inhibited by RNase A class inhibitors such as RNasin (Lee 
et al., 1998b). Major cleavage occurs at two sites in the first 8 8  nucleotides of the A-rich 
region, 5’-CAAUGAAAAG-3’, which corresponds to nucleotides 1727 to 1736 (Lee et ah, 
1998b). The identity of this endonuclease remains unknown.
Dicer
Dicer is a 218 kDa RNase III orthologue (Parker et ah, 2004; Provost et ah, 2002) 
implicated in RNAi and miRNA function, and is thought to be activated upon infection with 
viruses containing double-stranded RNAs (Rand et ah, 2004; Zhang et ah, 2004). In an in 
vitro setting. Dicer attacks the ends of double-stranded RNA with no sequence specificity 
into small interfering RNAs of -21 nucleotides and excises miRNAs that act to promote
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RNA interference (Doi et al., 2003; Fortin et al., 2002; Nicholson and Nicholson, 2002; 
Provost et al., 2002; Rand et al., 2004; Zhang et al., 2004).
Argonaute2
Argonaute2 is a component of RISC that recognizes and cleaves mRNAs that are 
complementary to the siRNAs (Hutvagner and Zamore, 2002; Schwarz et al., 2002). This 
protein is thought to be ~40 kDa in size due to the presence of the -20  kDa PAZ domain and 
-20  kDa PIWI domain (Liu et al., 2004; Parker et al., 2004). The PIWI domain, which is 
located in the C-terminal is thought to contain the endonucleolytic domain, based solely on 
structural similarity of this region with RNase H (Parker et al., 2004).
An endonuclease that cleaves B-globin mRNA
A polysomal endoribonuclease has been purified from mouse erythroleukemia cells and is 
thought to cleave normal (3-globin (Stevens et al., 2002). In addition, the polysomal 
endonuclease is also believed to be activated by the presence of a premature termination 
codon to cleave aberrant mRNAs (Stevens et al., 2002). It preferentially cleaves single- 
stranded UG (3’ to uridines) dinucleotides and to some extent UC (3’ to uridines) sites 
(Stevens et al., 2002). These sites were also found to be cleaved in vivo using SI nuclease 
mapping and primer extension (Stevens et al., 2002). The size and identity of this 
endonuclease are not known.
ErEN
ErEN is a -  40 kDa endonuclease that is part of a multiprotein complex ( -  160 kDa) and 
functions to cleave within the 3’ UTR region of a-globin mRNA (Rodgers et al., 2002; Wang 
and Kiledjian, 2000). It preferentially cleaves at nucleotide 63 (3’ to the cytidine residue in 
the CU dinucleotide) in the CU-rich element (Rodgers et al., 2002). It is not known, however.
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whether the cleaved dinucleotide is present in a single-stranded or a double-stranded region. 
The cleavage products were detected both in vitro and in vivo (Wang and Kiledjian, 2000).
It has been shown, in vitro, that a-globin mRNA becomes shielded from endonucleolytic 
degradation upon the binding of a protein complex, termed the alpha complex (a-CP), to the 
3’UTR (Rodgers et al., 2002; Wang and Kiledjian, 2000). It is also thought that the binding 
of the poly(A) binding protein to the poly(A) tail inhibits cleavage by ErEN (Rodgers et al., 
2002; Wang and Kiledjian, 2000). The precise identity of this endonuclease remains 
unknown.
An endonuclease that cleaves Tfr mRNA
A single-strand RNA specific endoribonuclease is thought to cleave within the 3’ UTR of 
the human transferrin receptor (Tfr) mRNA, more specifically, 3’ to the first guanosine 
residue within the 5’ GAACAAG 3’ motif (Binder et al., 1994). This enzyme is thought to be 
regulated by iron levels in the cytoplasm (Posch et al., 1999). When iron is scarce, a binding 
protein termed the Iron-Responsive Element Binding Protein (IREBP) binds to the iron- 
responsive element (IRE) in the 3’ UTR (Binder et al., 1994). However, when iron is 
abundant, the IREBP is displaced and the Tfr mRNA is cleaved within the 3’ UTR of the IRE 
(Binder et al., 1994; Rodgers et al., 2002). The size and identity of this endonuclease are not 
known.
An endonuclease that cleaves IGFII mRNA
Another single-strand RNA-specific endonuclease includes the enzyme that was found 
to cleave within the 3’ UTR of the Insulin Growth Factor II (IGFII) mRNA (Meinsma et al., 
1992; van Dijk et al., 1998; van Dijk et al., 2001). This endonuclease cleaves within purine- 
rich regions located between a putative hairpin structure and a guanosine-rich sequence
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(Nielsen and Christiansen, 1992). It is also thought that an RNA binding protein termed the 
IGFII Cleavage Unit Binding Protein (ICU-BP) interacts with the stem structure to shield 
IGFII mRNA from endonucleolytic cleavage (Scheper et al., 1996). The size and identity of 
this endonuclease remain unknown.
A ~ 120 kDa endonuclease that cleaves Xlhhox2B mRNA
A -  120 kDa endonuclease purified from Xenopus oocytes was found to cleave the 
Xenopus homeobox mRNA, Xlhbox2B, with the same specificity both in vitro and in vivo 
(Brown and Harland, 1990). The site of this cleavage is between the coding region and a 600 
nt region in the 3’ UTR (Brown and Harland, 1990), and is also the site of RNA binding 
proteins that act to shield the mRNA from endonucleolytic attack (Rodgers et al., 2002). 
The identity of this endonuclease remains unknown.
An endonuclease that cleaves mRNA
The mRNA of the cell-cycle regulator, p2?'^'^\ is thought to he cleaved 
endonucleolytically 3’ to the uridine residue (in bold) within the U-rich element, 5’- 
GUUUUGUUUUUUUU-3’ present in the 3’UTR (structure specificity of the enzyme is not 
yet unknown) (Zhao et al., 2000). This U-rich element is also the binding site of HuR, which 
is an mRNA-binding protein implicated in the stability of many mRNAs (Brennan and Steitz, 
2001; Zhao et al., 2000). The size and identity of this endonuclease remain unknown.
ARD-1
The activator of RNA decay, ARD-I is a cDNA encoded by human cells whose 
endoribonucleolytic activity was found to be similar to E.coli RNase E (similar cleavage 
sites) (Claverie-Martin et al., 1997). It was found to be 13.3 kDa in size and cleaves single-
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stranded regions only within AU rich elements (Claverie-Martin et al., 1997). This 
endonuclease has sequence homology to RNase E (Claverie-Martin et al., 1997).
An endonuclease that cleaves apolipoprotein II mRNA
An endonuclease has heen purified from chicken liver and is thought to cleave within the 
3’ UTR of the apolipoprotein II mRNA (Binder et al., 1989; Hua et al., 1993). More 
specifically, it preferentially cleaves 3’ to any adenosine or uridine within single-stranded 5’- 
AAU-3’ and 5’-UAA-3’ elements present in the 3’ UTR (Binder et al., 1989; Hua et al., 
1993). The size and identity of this endonuclease are not known.
A 60-70 kDa endonuclease that cleaves interleukin IT mRNA
An RNasin-resistant 60-70 kDa endonuclease purified from the cytoplasm of T 
lymphocytes was found to cleave interleukin II mRNA (Hua et al., 1993). This cleavage 
occurred within the 5’UUAUUUAU 3’ motif present in the coding region (structure 
specificity and exact sequence cleaved is not known) (Hua et al., 1993). The identity of this 
endonuclease remains unknown
26
Table 1.3. Vertebrate mRNA-endonucleases and their cleavage sites.
mRNA Cleavage site Name of 
endonuclease
Putative 
binding protein
mRNA-specificity of binding-proteins
Albumin Single-stranded 5’ ApyrUGA-3’ (3’ to 
uridine residue in bold) ; 3 -UTR
PMR-1 - -
Vitellogenin Single-stranded ApyrUGA (3’ to uridine 
residue in bold); 3 -UTR
PMR-1 Vigilin 3’UTR containing the 2 cleaved ApyrUGA sequences 
(Cunningham et ah, 2000)
c-myc Single-stranded , 5’CA 3’ dinucleotides RasGAP- 
associated G3BP
- -
c-myc 5’ CAAUGAAA 3’; coding region 
(A-rich-region)
- CRD-BP CRD region (nucleotides 1705-1786) (Prokipcak et ah, 
1994)
c-myc Single-stranded 5’-AUUUA-3’ in 3 ’UTR RNase E-like 
endonuclease
- -
Complementary 
mRNA to siRNA
- Argonaute2 - -
P-globin mRNA Single-stranded 5’ UG 3’ and 5 ’ UC 3 ’; 
3’UTR
- - -
a-Globin 5’ CCCUCCUUCCACC 3’ (cleaves 3 ’ 
to the C residue in bold)’; 3 ’-UTR
ErEN aC P 5’CCGAUGGGCCUCCCAACGGGCCCUCCUCCC 
CUCCUUGCACC3’; 3’UTR (Wang and Kiledjian, 
2000).
Tfr Single-stranded , 5’ GAACAAG 3’ 
(cleaves 3’ to the guanosine residue in 
bold); 3 ’-UTR
IREBP Stem-loops B and E (near cleavage site); 3’ UTR 
(Koeller et ah, 1989)
IG FII Single-stranded; Adjacent to G-rich 
sequence and duplex structure ; 3 ’ UTR
ICU-BP Elements I and II; 3 ’UTR (element II contains cleavage 
site) (Scheper et ah, 1996).
Xlbbox2R 5’ CACCCUACCUACCCAACUA 3’ - Endonuclease
inhibitor
Not identified
HBV RNA Single-stranded 5 ’ CCAUACU 3’ 
(3’ to adenosines in bold)
La antigen Stem-loop 2 (nts 1272-1295) containing the last 3 
nucleotides of the consensus cleavage site (5’ACU 3’) 
(Heise et ah, 1999a; Heise et ah, 1999b)
P27*^p' 5 ’GUUUUGUUUUUUU 3’ (3’ to the 
uridine residue in bold); 3 ’UTR
- HuR U-rich element in 3’ UTR containing cleavage sites 
(Zhao et ah, 2000)
Viral RNA Single-stranded 5 ’ UA 3’ and 5’UU 3’ RNase L - -
Viral RNA Double-strand RNA Dicer - -
- Single-stranded AU rich regions ARD-1 - -
Apolipoprotein II Single-stranded 5 ’-UAA-3’ and 5 ’AUU- 
3’ trinucleotides; 3 -UTR
- - -
11-2 5’ UUAUUUAU 3’, coding region - - -
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1.3 A novel mammalian endoribonuclease that was identifled based on its ability to 
cleave a specific coding region of c-myc RNA in vitro
1.3.1 Significance of this endoribonuclease
During the development of an improved purification strategy to purify the -39  kDa 
endonuclease that cleaves the c-myc CRD RNA (Lee et al., 1998b), another novel 
endoribonuclease comprising of five polypeptides was accidentally discovered (Bergstrom et 
al., in press). The purpose of this project is to characterize the sequence/structure cleavage 
specificity of this mammalian endoribonuclease to the 1705-1792 c-myc CRD region.
In rodent livers, c-myc mRNA levels increase transiently following partial 
hepatoectomy and then decrease as liver regeneration is completed (Kren et al., 1996). These 
fluctuations in mRNA levels were determined to be independent of the c-myc gene promoter, 
but rather relied heavily on a c-myc mRNA c/^-element, namely the coding region 
encompassing the CRD (Morello et al., 1990). The implication of c-myc mRNA decay in 
controlling gene expression in the liver is further supported by the observations that c-myc 
mRNA is cleaved endonucleolytically in cells (Hanson and Schoenberg, 2004; Pistol et al., 
1996), and that it was found to be relatively stable in liver cancer (Lee et al., 1998a). 
Therefore, the study of an enzyme that has the capability of degrading c-myc mRNA has the 
potential to enhance our knowledge of mammalian mRNA stability and provide insight into 
how c-myc mRNA is post-transcriptionally regulated.
In addition, the significance of understanding and identifying this endonuclease stems 
from the fact that little, in general, is known about mammalian endonucleases. Knock-out 
experiments such as the one performed against the RasGap-G3BP and RNase L genes have 
highlighted the significance and role of endoribonucleases in vivo. Vigorous investigations 
into the role of the endonuclease under study are required. For instance, it is not known if this
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endonuclease is stress-regulated, similar to endonucleases such as RNase L, Dieer, PMR-1, 
and the endonucleases capable of cleaving the Tfr and HBV RNAs. It is also not known if the 
endonuclease under study is part of a larger protein complex that regulates c-myc gene 
expression. Lastly, further studies on this endonuclease will confirm whether it is distinct 
from the other endonucleases capable of cleaving c-myc mRNA such as RasGAP-associated 
G3BP, the -65 kDa RNase-E like enzyme, and the -39 kDa endonuclease.
1.3.2 The signincance of determining RNA secondary structure
There are two essential properties of RNA molecules: first, that they intrinsically 
form stable secondary structures both in vivo and in vitro, and second, that secondary 
structural features play a critical role in regulating several cellular process (Buratti and 
Baralle, 2004; Klaff et al., 1996). As indicated previously, endonucleases may cleave their 
target sequences in single-stranded regions only, double-stranded regions only, or in both. 
Therefore, in order to characterize the sequence and structural specificity of the mammalian 
endonuclease to the CRD region of c-myc mRNA, the secondary structure of the CRD RNA 
corresponding to nts 1705-1792 of c-myc must first be determined.
In addition to mRNA turn-over, RNA secondary structures are thought to be involved 
in cellular process such as splicing (Buratti and Baralle, 2004), protein-binding (Buratti and 
Baralle, 2004), translation (Doktycz et al., 1998), and pathogenesis (Buratti and Baralle, 
2004). Most chloroplast mRNAs, for example, contain a stem-loop structure in the 3’UTR 
which renders the mRNA stable by impeding 3’ to 5’ exonucleases from attacking them 
(Yang and Stern, 1997). Removal of this stem-loop thus renders the mRNA unstable and 
decreases its half-life (Yang and Stern, 1997). Secondary structural features are also thought 
to play a role in the processing of yeast precursor mRNAs (Buratti and Baralle, 2004). In
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Saccharomyces cerevisiae, it is thought that secondary structures between the 5’ splice site 
and the branch point are capable of promoting UlsnRNP assembly in the early splicing 
stages (Buratti and Baralle, 2004; Charpentier and Rosbash, 1996). Stem-loops have also 
been implicated in putative protein-binding. The HuR protein, for example, is involved in 
mRNA turn-over by binding to specific mRNA subsets and this relies heavily on secondary 
structural features (Buratti and Baralle, 2004).
mRNA translation is another cellular process which is thought to involve secondary 
structural features (Doktycz et al., 1998). It is thought that RNA secondary structures 3’ to 
the initiation codon can enhance the efficiency of translation by slowing the initiation-codon 
scanning mechanism, and that structural features in the 5’ UTR strongly inhibit translation 
(Doktycz et ah, 1998). In addition to splicing, secondary structural features have also been 
implicated in pathogenesis. Mutations in the tau gene have been implicated in diseases such 
as frontotemporal dementia and Parkinson’s disease (Buratti and Baralle, 2004). NMR 
studies have shown that mutations in the intronic region near the 5’ splice site of exon 10 of 
the tau gene strongly correlates with an alternate secondary structure (Buratti and Baralle,
2004).
1.4 Objectives
The novel rat liver endonuclease, which consists of five polypeptides, has been 
purified based on its ability to cleave within the CRD of c-myc mRNA in vitro (Bergstrom et 
ah, in press). The full-length CRD region corresponds to nts 1705-1886 of the c-myc mRNA, 
whereas the region used to purify the novel endonuclease corresponds to nucleotides 1705- 
1792 (Figure 1.2). The 1705-1792 CRD RNA was used for the characterization of the novel 
endonuclease.
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5'-UTR Coding Rcgioa
c-myc mRNA CRD
Full-length c-myc Coding Region
Determinant RNA (FL-RNA; nts 1705-1886)
5 -CRD RNA (substrate for liver 
endonuclease; nts 1705-1792) ^2p
Figure 1.2. A Schematic representation illustrating the full CRD region (1705-1886) and the 
1705-1792 CRD region. The 1705-1792 CRD region was used for the study of the sequence 
and structure cleavage specificity of the novel mammalian endonuclease.
The first aim of this project was to determine the in vitro seeondary strueture of the 
CRD region spanning nts 1705-1792. Seeondary structure determination of the CRD region 
will allow: (i) determination of whether the enzyme preferentially eleaves its target 
sequences in single-stranded or double-stranded regions or both, (ii) an understanding of the 
potential secondary structure of the 1705-1792 CRD region in vivo, (iii) an understanding of 
the potential eleavage specifieity of the endonuclease in vivo. The second aim of this project 
was to characterize the sequence/structure cleavage speeificity of the novel mammalian 
endonuclease by generating a series of mutants eneompassing nts 1705-1792 of the CRD 
region. To confirm the sequence and strueture specificity of the mammalian endonuclease, 
P-globin RNA (3018-3159) was randomly ehosen as a substrate for this study. Determination 
of the sequence and structural specificity of the endonuclease to the CRD mutants will: (i) 
confirm whether the endonuclease is a single-stranded or a double-stranded RNA-cleaving 
enzyme, (ii) confirm the sequence specifieity of the endonuelease to the RNA, (iii) constitute 
the first step toward understanding the sequenee and struetural specificity of the 
endonuclease in vivo, (iv) confirm whether the endonuclease is indeed a novel mammalian 
endonuclease, distinct from other currently known vertebrate endoribonueleases.
31
Chapter 2
In Vitro Secondary Structure Détermination of the 1705-1792 Coding Region 
Determinant (CRD) Region of the c-myc mRNA and the P-globin mRNA 
Corresponding to Nucleotides 3018-3159.
This chapter aims at determining the secondary structure of the in vitro-transcribed 1705- 
1792 CRD RNA and the RNA corresponding to nts 3018-3159 of P-globin. This is 
accomplished by using the Mfold software program, in conjunction with RNase probing 
experiments. Determination of the secondary structure of the 1705-1792 CRD RNA will 
provide insight into the structure specificity requirement for cleavage by the novel 
mammalian endonuclease under study. In addition, secondary structure determination of the 
3018-3159 p-globin RNA will further confirm the sequence and structure specificity 
requirement for RNA cleavage by the novel enzyme.
2.0 Methods
2.0.1 Linearization and in vitro transcription of the pUC19 and the SPkPc plasmids 
containing the 1705-1792 CRD DNA insert and nucleotides 3018-3159 of the P-globin 
DNA, respectively.
The pUC19 plasmid (5 ug) containing the 1705-1792 c-myc cDNA (5’-ACCAGATCC 
CGGAGTTGGAAAACAATGAAAAGGCCCCCAAGGTAGTTATCCTTAAAAAAGCCA 
CAGCATACATCCTGTCCGTCCAAGC-3’) and an SP6  promoter site (5’ to the cDNA) 
was linearized with the restriction enzyme EcoRl (Invitrogen Life Technologies, Carlsbad, 
CA) in a 20 uL final volume consisting of the following final concentrations: 1 U/uL of 
EcoKl, IX Reaction Buffer, and made up to volume with sterile water. The digestion was 
performed at 37°C for 3 hours. After linearization, 1 uL of the linearized plasmid and 1 uL of 
the uncut plasmid were run on a 1% agarose gel to check for digestion. The gel was run for 
about 1.5 hours at 46 mA and was visualized using the Chemilmager^*^ System (Alpha
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Innotech Corporation, San Leandro, CA). The reaction mixture was then made up to 200 uL 
with sterile water in preparation for the standard phenol/chloroform extraction. This involves 
adding Vz volume of phenol (100 uL) and Vi volume of chloroformdsoamylaleohol (CHCI3 : 
lAA) (49:1). The solution was mixed thoroughly by repeated inverting and then was 
centrifuged at 12,000 rpm for 5 minutes. The aqueous layer (top layer) containing the 
linearized plasmid was earefully extracted and one volume of CHCI3 : lAA was subsequently 
added. The solution was then mixed again by inverting and then centrifuged at 12,000 rpm 
for five minutes. The top layer was then extracted again and standard ethanol precipitation 
was performed. Standard ethanol preeipitation involves the addition of 1/10* volume of 3M 
sodium acetate (NaAc) pH 5.2, followed by two volumes of 100% ethanol, mixing 
thoroughly by inverting, and DNA preeipitation at -20°C for at least 15 minutes. The 
solution was then centrifuged at 1 2 , 0 0 0  rpm for 1 0  minutes and the supernatant was then 
gently poured off. Seventy percent ethanol was then added (200 uL) to the DNA pellet and it 
was again centrifuged for 5 minutes at 12,000 rpm. The supernatant was then earefully 
removed and the pellet was allowed to dry at room temperature for 15 minutes. The dried 
pellet was resuspended in sterile water to a final concentration of 0.2-0.3 ug/uL.
The linearized plasmid (1 ug) was then used as a template for in vitro transcription 
using the MEGAscript SP6  Kit (Ambion, Inc., Austin, Texas). The transcription reaction was 
performed in a 20 uL final volume containing the following reagents: IX reaction buffer, 5 
mM rNTPs, 8  mM DTT (Invitrogen Life Technologies, Carlsbad, CA), 3 units/pl of RNasin 
(Promega, Madison, WI), and 2 uL of the SP6  enzyme mix. The in vitro transcription 
reaction was performed at 37°C for 1.5 hours, followed by the addition of 1 uL DNase I 
(Ambion, Inc., Austin, Texas) and incubation at 37°C for 15 minutes. The reaction mixture
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was then made up to 200 uL with diethylpyrocarbonate (DEPC) H2O, followed by standard 
phenol/chloroform extraetion and standard ethanol precipitation. The RNA pellet was then 
resuspended in 50 uL DEPC-H2O and the unincorporated rNTPs were removed using the 
ProbeQuant^'^ G-50 Micro Column (Amersham Bioscienees UK Limited, Little Chalfont, 
Buckinghamshire, England) according to the manufacturer’s protocol. To check the quality 
of the RNA, 1 uL of the RNA sample was added to 5 uL cocktail mix [10 X MOPS (N- 
morpholino propanesulfonie acid, EDTA, sodium acetate, sterile water, DEPC-H2O), 
formaldehyde, formamide, ethidium bromide, and DEPC-H2O) and 2 uL loading dye, and 
run on a 1.3% agarose gel (containing formaldehyde) at 50 mA for 1 hour. The RNA was 
visualized using the Chemilmager™ System.
The S P k (3c plasmid (5 pg) containing nucleotides 3018-3159 of the human (3-globin DNA 
(5 ’ AC ATTTGCTTCTGAC ACAACTGTGTTC ACT AGO AACCTC AAAC AG 
ACACCATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGC 
A AGGTGA ACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAG-3 ’ ) was linearized 
with the restriction enzyme Fokl (New England Biolabs, Beverly, MA) in a 20 uL final 
volume consisting of the following final concentrations: 1 U/uL of Fokl, IX React 2, and 
made up to volume with sterile water. The digestion was performed at 37°C for 3 hours. 
Subsequent steps were identical to the ones described for the pUC19 plasmid. The in vitro 
transcription reaction was performed using the MEGAscript SP6  Kit (Ambion, Inc., Austin, 
Texas), identical to the procedure described for the 1705-1792 CRD RNA.
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2.0.2 Déphosphorylation, 5’-end labeling, and gel-purification of the 1705-1792 CRD 
and the 3018-3159 p-glohin transcripts.
In order to 5’ end-label the transcript with y^^P-ATP, it was necessary to dephosphorylate 
the 1705-1792 CRD transcript. Dephosphorylation was performed in a 100 uL final volume 
consisting of the in vitro transcribed 1705-1792 CRD RNA (9 ug) and the following 
reagents, having the final concentrations of: 0.1 U/uL Calf Alkaline Phosphatase (ClAP) 
(Roche Diagnostic Inc, Mannheim, Germany), IX dephosphorylation buffer, 0.4 units/pl of 
RNasin, 5 mM DTT, and made up to 100 uL with DEPC-H2O. The reaction mixture was then 
incubated for 30 minutes at 37°C. After making up the volume to 200 uL with DEPC-H2O, 
the following reagents were added to ensure the dissociation of protein-RNA complexes and 
the denaturing of ribonucleases (Boyer, 1992): 1 uL of 0.5M EDTA pH 8 , 4 uL of 5 M NaCl, 
and 10 uL of 20% SDS. The standard chloroform/phenol extraction was then performed, 
followed by ethanol precipitation, and resuspension of the pellet using DEPC-H2O to give a 
final concentration of 0.25-0.5 |ig/pL. The dephosphorylated RNA was checked on a 1.3% 
agarose gel to ensure the presence of RNA before proceeding with 5’-end labeling.
The 5’-end labeling of the dephosphorylated transcript was performed in a 25 pL final 
volume consisting of 5 pg of the dephosphorylated transcript and 30 pCi of y^^P-ATP 
(Amersham GE Healthcare, Montreal, Quebec). End-labeling of the RNA was done using the 
following reagents with final concentrations of: 12 mM DTT, 2.5 U/pL of RNasin, 1.6 U/pL 
of T4 Polynucleotide Kinase (PNK) (New England Biolabs, Beverly, MA), IX PNK buffer, 
and made up to 25 pL with DEPC-H2O, followed by incubation for 1 hour at 37*^ C. After 
making up the reaction mixture to 50 pL with DEPC-H2O, the excess y^^P-ATP was removed 
using a G-50 spin column and the solution was then made up to 200 pL with DEPC-H2O,
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followed by phenol/chloroform extraction and ethanol precipitation. The pellet was 
resuspended in 20 pL 9M urea/phenol loading dye (0.02% w/v bromophenol blue, 0.02% 
w/v xylene cyanol, and 10% v/v saturated phenol) and loaded onto a 6 % polyacrylamide/7M 
urea gel, which was run at 25 mA with 0.5X TBE buffer (tris base, boric acid, EDTA) until 
the bromophenol dye was near the bottom of the gel. The gel was then exposed for 10 
seconds, scanned using the Cyclone Phospholmager and visualized using the OptiQuant 
software (Hewlett Packard, Palo Alto, CA). The portion of the polyacrylamide gel 
containing the 1705-1792 radioactively-labeled RNA transcript was excised and the ^^P- 
labeled RNA was eluted with 400 pL of Probe Elution Buffer [PEB(NH4 0 AC, EDTA pH 8 , 
SDS, and DEPC-H2O)]: Phenol (1:1) solution for 6  hours at 37‘^ C, followed by standard 
phenol/chloroform extraction and ethanol precipitation. The radioactive pellet was then 
resuspended in approximately 100 pi DEPC-H2O to give a final count of approximately 
30,000 cpm/pL.
Dephosphorylation, 5’-end labeling, and gel-purification of the 3018-3159 (3-globin 
transcript was identical to the procedure described for the 1705-1792 CRD RNA.
2.0.3 Utilization of enzyme probes for secondary structure determination
The 5’-end labeled 1705-1792 RNA transcript (30,000 cpm) was partially digested with 
RNase T1 (cleaves 3’ to single-stranded guanosines) (Roche Diagnostic Inc, Mannheim, 
Germany), RNase T2 (preferentially cleaves 3’ to single-stranded adenosines, but also 3’ to 
the other 3 nucleotides) (Invitrogen Life Technologies, Carlsbad, CA), RNase A (cleaves 3’ 
to single-stranded uridines and cytidines) (Ambion, Inc., Austin, Texas), and RNase VI 
(cleaves 3’ to double-stranded nucleotides or stacked bases) (Ambion, Inc., Austin, Texas) 
(Ehresmann et al., 1987) (see Table 2.1 for a summary of the RNase probes and their
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cleavage sites). Digestion by RNase T1 was done under both RNA native and denaturing 
conditions in order to confirm the strandedness of the guanosine residues. Digestion of the 5’ 
end-labeled transcript under RNA denaturing conditions was done in IX sequencing buffer 
containing 20 mM sodium citrate pH 5, 7M urea, and 1 mM EDTA (Ambion, Inc., Austin, 
Texas), which according to Ehresmann et al. (1978), RNase T1 remains active under these 
conditions. Digestion of the transcript under native conditions was done in a buffer 
containing 100 mM Tris-HCl pH 7.5, IM NH4CI, and 100 mM MgCli (lOX PA buffer). 
Digestion of the 5’ end-labeled transcript with RNase T2, RNase A, and RNase VI was done 
in a buffer consisting of 100 mM Tris pH 7, IM KCl, and 100 mM MgClz (lOX Structure 
Buffer) (Ambion, Inc., Austin, Texas). In order to identify the cleavage sites that were 
generated, a partial alkaline digestion of the end-labeled transcript was done (Ehresmann et 
al., 1987). This involved incubation with lOX alkaline buffer containing 50 mM sodium 
carbonate (NaHC0 3 /Na2C0 3 ) pH 9.2, and 1 mM EDTA. The alkaline ladder and enzyme 
digestions were all performed in a 2 0  (tl final volume containing 2  (tl of the respective 
reaction buffer, the 5’ end labeled transcript (30,000 cpm), and made up to 20 |il with sterile 
water. Partial alkaline digestion was done at 95°C for 3 minutes, followed by ethanol 
precipitation and resuspension in 9M urea/phenol loading dye to give final counts of 25,000 
cpm/pl and then loading 2 pi. Prior to enzymatic digestion, the RNA transcript was heated 
for 5 minutes at 50-55°C and then allowed to refold for 10 minutes at room temperature. 
Partial digestion of the RNA transcript with RNase T1 under RNA denaturing eonditions 
involved the addition of 1 unit of RNase T1 and then incubation at room temperature for 5 
minutes, whereas for partial digestion under RNA native conditions, 0.05 units of RNase T1 
was added and incubation was done for 30 seconds on ice. Partial digestion with RNase T2
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(0.02 units) and RNase A (2 x lO'"^  mg) was performed for 15 minutes at room temperature, 
whereas for RNase VI (1 x 10'"^  units), the mixture was incubated for 5 minutes at room 
temperature. The reactions were terminated by the addition of 1 pi saturated phenol and 1 pi 
yeast tRNA (10 mg/ml), followed by standard ethanol preeipitation and resuspension in 9M 
urea/phenol loading dye to give final counts of 15,000 epm/pl. Two mierolitres of samples 
were typically loaded onto the gel for visualization. To cheek for RNA integrity, undigested 
1705-1792 CRD RNA was also ran (input RNA).
After pre-running the 12% polyaerylamide/7M urea gel with 0.5X TBE buffer for 45 
minutes, the samples were loaded and the gel was run for 2.5 hours at 30 mA until the 
bromophenol dye was near the bottom of the gel. The gel was then fixed in 10% 
methanol/1 0 % acetic acid solution for 1 0  minutes, exposed for 16 hours, scanned using the 
Cyclone Phospholmager and visualized using the OptiQuant software.
Strueture probing of the 3018-3159 (3-globin RNA was identical to the procedure 
described for the 1705-1792 CRD RNA, except for the following modifications. The 3018- 
3159 P-globin RNA was incubated with 1 unit of RNase T1 for 15 minutes at room 
temperature under both RNA denaturing and RNA native conditions. In addition, the 3018- 
3159 p-globin RNA was incubated with 1 pi of 1X10'^ U/pl RNase VI for 15 minutes at 
room temperature. After loading the samples onto the gel, the samples were run for two 
hours and four hours under the same electrophoresis conditions described for the 1705-1792 
CRD RNA.
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Table 2.1 The enzymes probes and their cleavage specificity.
Enzyme Probe Cleavage specificity
RNase T1 3’ to unpaired guanosines
RNase T2 3’ to unpaired adenosines > guanosines, cytidines, uridines
RNase A 3’ to unpaired cytidines and uridines
RNase VI 3’ to paired or stacked nucleotides
2.1 Results
2.1.1 Digestion of the pUC19-myc 1705-1792 and SPKPc-globin 3018-3159 plasmids and 
the generation of in vitro transcribed RNA 
pUC19-myc 1705-1792 plasmid
Upon agarose gel electrophoresis, the undigested pUC19 plasmid containing the 1705- 
1792 CRD insert showed two bands (Figure 2.1). The intense, low molecular band at 
approximately 2,500 bp represented the supercoiled conformation of the plasmid, whereas 
the faint high-molecular weight band corresponded to the relaxed form of the recombinant 
pUC19 plasmid (nicked plasmid). Upon digestion of recombinant pUC19 with EcoRl, one 
band that ran between the nicked and the supercoiled plasmids was observed, indicating that 
most, if not all, of the recombinant pUC19 plasmids were linearized.
The linearized plasmid was then used as a template for in vitro transcription using SP- 6  
RNA polymerase. Upon agarose gel electrophoresis, a single band was observed at 
approximately 90 nucleotides (Figure 2.2). This band represented the 8 8  nucleotide 1705- 
1792 RNA, in addition to the BamHI and EcoRI restriction sites.
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Figure 2.1. Linearization of 1705-1792 pUC19 plasmid with EcoRl in preparation for in 
vitro transcription. The undigested pUC19 plasmid (lane 2) was compared to an EcoRl 
digested plasmid (lane 3) parallel to a 1 Kb DNA ladder (lane 1). The samples were run on a 
1% agarose gel containing ethidium bromide and visualized using Chemilmager™ System 
(Alpha Innotech Corporation, San Leandro, CA).
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Figure 2.2. In vitro transcription using the 1705-1792 pUC19 plasmid as a template. The 
linearized 8257 pUC19 plasmid was in vitro transcribed using the MEGAscript SP6  Kit 
(Ambion, Inc., Austin, Texas) and ran on a 1.3% agarose gel. Lane 1 represents the RNA 
ladder and lane 2 corresponds to the in vitro transcribed 1705-1792 CRD RNA.
SPKBc-globin 3018-3159 plasmid
Upon agarose gel electrophoresis, the undigested SPK(3e-globin plasmid was represented 
by four bands at approximately 2,500 bp, 3,000 bp, 5,000 bp, and 12,000 bp (Figure 2.3). 
The band at 5,000 bp may represent the relaxed form of the recombinant plasmid, while the 
band at 2,500 bp may represent the supercoiled form of the plasmid. The 3,000 bp band may 
represent the linearized form of the plasmid, which might have been present due to 
contamination with restriction endonucleases that were left behind from the bacterial crude 
extract or it might have been due to mechanical shearing of the plasmid. The band at 12,000
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bp may represent multimerization of the SPKPc-globin plasmid, to generate this slow-running 
complex. Upon cleavage of the SPKpc-globin plasmid with Fok\, three bands were generated 
at approximately: 650 bp, 700 bp, and 1,000 bp (Figure 2.3). These bands were most likely 
due to the digestion of the plasmid at the multiple Fok\ restriction sites.
The linearized plasmid was then used as a template for in vitro transcription using the SP- 
6  RNA polymerase. In a 1% formaldehyde agarose gel, one major band was observed 
between the 100 and 200 nucleotide markers (Figure 2.4). This is in good agreement with the 
expected size of the 142 nt p-globin RNA (3018-3159).
12,000-
5.000-
Figure 2.3. Linearization of the SPKpc-globin 3018-3159 plasmid with Fokl in preparation 
for in vitro transcription. The undigested SPKPc-globin 3018-3159 plasmid (lane 2) was 
compared to an Fokl digested plasmid (lane 3) parallel to a 1 Kb DNA ladder (lane 1). The 
samples were run on a 1 % agarose gel containing ethidium bromide and visualized using 
Chemilmager^"^ System (Alpha Innotech Corporation, San Leandro, CA) (Courtesy of Dan 
Sparanese).
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nt
500-
100-
3018-3159 beta-globin RNA
Figure 2.4. In vitro transcription using the 3018-3159 P-globin plasmid as a template. The 
linearized 3018-3159 P-globin plasmid was in vitro transcribed using the MEGAscript SP6  
Kit (Ambion, Inc., Austin, Texas) and ran on a 1.3% agarose gel. Lane 1 represents the RNA 
ladder and lane 2 corresponds to the in vitro transcribed 3018-3159 P-globin RNA (Courtesy 
of Dan Sparanese).
2.1.2 Visualization of the gel-purified 5’-end labeled RNA on a 6% polyacrylamide/ 
7M urea gel
c-mxc nts 1705-1792
In order to obtain an uncontaminated RNA substrate for secondary structure determination 
and cleavage specificity analysis, the 5’ end-labeled transcript was gel-purified on a 6 % 
polyacrylamide/7M urea gel. On a 6 % denaturing polyacrylamide gel, the xylene cyanol
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(XYC) dye has a size of 106 nt, while the bromophenol blue (BPB) dye has a size of 26 nt. 
Therefore, the 1705-1792 CRD RNA ( - 8 8  nucleotides) is expected to migrate slightly faster 
than xylene cyanol dye. Upon running the labeled transcript on the polyacrylamide gel, an 
intense band slightly below the xylene cyanol marker was observed (see arrow; Figure 2.5a). 
This band corresponded to the 1705-1792 CRD RNA, which has an approximate size of 8 8  
nucleotides. In addition to this intense band, multiple faint degradation products were also 
observed (Figure 2.5a). Upon gel-purification, the 1705-1792 CRD bands were successfully 
excised, leaving behind most of the unwanted degradation products (Figure 2.5b).
a) b)
1705-1792 
CRD RNA
XYC (106nt) 
<  ►
< — ►
BPB (26nt)
Figure 2.5. Gel-purification of the 5’ end-labeled 1705-1792 CRD transcript. The 5’ end 
labeled transcript was run on a 6 % polyacrylamide/7M urea gel and the samples were divided 
into 3 wells (a). After gel-purification, the gel was re-exposed for 10 seconds and visualized 
to ensure the excision of the 1705-1792 CRD RNA (b). XYC and BPB indicate the 
approximate locations of the xylene cyanol and the bromophenol dyes, respectively.
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B-globin nts 3018-3159
Upon running the ^^P-labeled P-globin RNA on a 6 % polyacrylamide/7M urea gel, an 
intense band corresponding to the ~ 142 nt 3018-3159 P-globin RNA was observed, in 
addition to multiple degradation products (Figure 2.6a). The 3018-3159 p-globin RNA 
migrated slightly slower (ban the xylene cyanol band (106 nt) (Figure 2.6a). The 3018-3159 
p-globin RNA was successfully excised from the gel, leaving behind most of the unwanted 
degradation products (Figure 2.6b).
a) b)
3018-3159,
beta-globin RNA
XYC 
(106 nt)
BPB
(26 nt)
Figure 2.6. Gel-purification of the 5’ end-labeled 3018-3159 P-globin transcript. The 5’ end 
labeled transcript was run on a 6 % polyacrylamide/7M urea gel and the samples were divided 
into 4 wells (a). After gel-purification, the gel was re-exposed for 10 seconds and visualized 
to ensure the excision of the 3018-3159 P-globin RNA (b). XYC and BPB indicate the 
approximate locations of the xylene cyanol and bromophenol dyes, respectively (Courtesy of 
Dan Sparanese).
45
2.1.3 The secondary structures of the 1705-1792 c-myc CRD and 3018-3159 P-globin 
RNAs in vitro
c-mvc nts 1705-1792
The 5’ end-labeled 1705-1792 CRD transcript digested with the different RNases was run 
on a 12% polyacrylamide/7M urea gel for 2 hours (Figure 2.7a) and 3 hours (Figure 2.7h), 
respectively, in order to obtain a better resolution of cleavage sites near the top and bottom of 
the gel. However, only the cleavage sites between nucleotides 1719 and 1780 of the CRD 
region were easily identifiable upon running the gel for the indicated time periods.
Upon digestion of the labeled transcript with RNase T1 under RNA-denaturing 
conditions, it appeared that the 1705-1792 RNA substrate has been completely digested 
(Lane 3). This was not the case, however, as will be explained in the discussion section. Six 
cleavage fragments were generated by RNase T1 under RNA-denaturing conditions: G 1731, 
G1745, G1746, G1749, G1764, and G1770 (Lane 3, Figure 2.7a). However, upon digestion 
of the 5’ end-labeled transcript with RNase T1 under RNA-native conditions, only fragments 
corresponding to G1731, G1749, and G1770 were observed (Lane 4, Figure 2.7a). It is 
important to point out that cleavage at G 1749 appeared more intense under native conditions 
than denaturing conditions (Lane 4, Figure 2.7a). Upon cleavage with RNase T2 under RNA 
native condition, a laddering pattern was observed and was mostly prominent between 
nucleotides 1719-1734, 1739-1744, 1747-1752, and 1768-1775 (Lane 5, Figure 2.7a). In 
addition, there was RNase T2 cleavage at positions U1757 and A1758. Digestion with 
RNase A generated several fragments including intense cleavage at C1727, UI751, C1768, 
CI771, UI773, and CI775 (lane 6, Figures 2.7 a and b). Weak cleavage sites generated by 
RNase A include C1741, C1742, U1747, and U1750. It is also important to note that all of 
the cleavage sites generated by RNase A were also cleaved by RNase T2 (Lanes 5 and 6,
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Figures 2.7 a and b). Cleavage with RNase VI generated two intense bands at positions 
A 1743 and C1768, in addition to the weak bands observed at positions C1771 and U1773 
(Lane 7). Furthermore, laddering patterns were observed between nucleotides 1721-1724, 
1727-1734, 1743-1745 and 1754-1757 (see Brackets 1-4, respectively; Figures 2.7a and 
2.7b).
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Figure 2.7. Structure probing of the 5’ end-labeled in vitro transcribed 1705-1792 CRD 
RNA on a 12% polyacrylamide/7M urea gel that was run for 2 hours (a) and 3 hours (b), For 
band identification purposes, guanosine residues on the left of the diagram indicate several 
sites cleaved by RNase T1 under RNA denaturing conditions, whereas numbering on the 
right indicates some of the sites cleaved by RNase A. Brackets 1-4 indicate the four laddering 
regions generated by RNase VI.
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upon folding the 1705-1792 CRD region using the Mfold software program (Zuker, 
2003), the secondary structure shown in Figure 2.8 was obtained. The RNase probing data 
was then used as a constraint with the structure generated by Mfold to obtain a structure that 
best fit the probing data (Figure 2.9). The experimental data is in agreement with the 
structure determined by Mfold, although the experimentally determined structure appeared to 
be very dynamic in solution. The experimental structure shown in Figure 2.9 consists of a 
summary of the cleavage sites and cleavage intensities generated at each position cleaved by 
the various RNases. Cleavage intensity was determined by judging the strength of each 
cleavage site relative to the overall cleavage within each lane. The secondary structure has 
five stems, two containing four base pairs (stems I and V) and the remaining three consisting 
of three base-pairs (stems II, III, and IV). In addition, there is one hairpin loop (nts 1747- 
1753) and four internal bulges consisting of an average of eight nucleotides (Figure 2.9).
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Figure 2.8. The 1705-1792 CRD secondary structure determined by the Mfold software 
program. This structure was generated hy entering the primary sequence into the Mfold 
program (Zuker, 2003) to obtain a structure with the lowest free-energy.
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Figure 2.9. Secondary structure model for the 1705-1792 CRD RNA showing locations of 
bases accessible for enzyme probes. This secondary structure was obtained by using the 
probing data as constraint with the Mfold program (Zuker, 2003). Hatched and open symbols 
represent moderate and weak cleavage, respectively, while filled symbols represent strong 
modification. RNase VI cleavage sites are indicated by arrow intensity. D and N indicate 
cleavage with RNase T1 under RNA denaturing or native conditions, respectively.
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B-globin nts 3018-3159
The 5'end-labeled 3018-3159 P-globin RNA transcripts digested with the different RNase 
probes were run on a 12% polyacrylamide/7M urea gel for 2 hours (Figure 2.10a) and 4 
hours (Figure 2.10b), respectively. This was done in order to obtain a better resolution of 
cleavage sites near the top and bottom of the gel. However, only cleavage sites between 
nucleotide 1 and 84 (numbering starts from the 5’ end) were easily identifiable upon running 
the gel for the indicated time periods.
Upon digestion of the 5’ end-labeled 3018-3159 P-globin RNA with RNase T l under 
RNA denaturing conditions, sixteen cleavage sites were easily identifiable: G7, G13, G22, 
G24, G32, G45, G53, G54, G62, G69, G71, G72, G74, G77, G81, and G84 (lane 3, Figures 
2.10 a and b). Upon cleavage of the labeled transcript with RNase T l under RNA-native 
conditions, the same cleavage sites generated by RNase T l under RNA denaturing conditions 
were also cleaved, except for G53 and G54 (lane 4, Figures 2.10 a and b). It is also important 
to point out that upon cleavage 3’ to G81 by RNase T l under RNA-native conditions, an 
intense cleavage fragment is obtained in comparison with the cleavage fragment generated by 
RNase T l under RNA denaturing conditions (lanes 3 and 4, Figure 2.10b). Cleavage of the 5’ 
end-labeled transcript with RNase T2 generated three laddering regions, in addition to 
cleavage 3’ to U80 and G81 (lane 5, Figure 2.10 a and b). The laddering regions were 
observed between nucleotides 1-12, 18-20, and 39-44 and include intense cleavage 3’ to A18 
and A19 (lane 4, Figure 2.10a). Upon partial digestion with RNase A, nineteen cleavage sites 
were generated including an intense cleavage 3’ to C2 (lane 6 , Figure 2.10a). The remaining 
eighteen sites cleaved by RNase A include: U4, U 6 , C8 , UlO, C l l ,  U12, C15, C17, C20, 
U21, C27, U30, C33, C39, C43, C47, C50, and U80. The following sites cleaved by RNase
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A were also cleaved by RNase T2: C2, U4, U 6 , C8 , UlO, U l l ,  U12, C20, C39, and C43. 
Upon cleavage of the 5’ end-labeled transcript with RNase V I, the following nucleotides 
were cleaved: C17, C27, C29, U30, A35, A39, and C5G (lane 7, Figure 2.10a and b). In 
addition, laddering regions were observed between nucleotides 1-6 and 10-15 (see Brackets 1 
and 2, respectively. Figure 2.10a). The following sites cleaved by RNase VI were also 
cleaved by RNase T2: 1-6, 10-12, and A39. Furthermore, RNase VI sites that were also 
cleaved by RNase A include: C2, U4-U6, UlO, C l l ,  U12, C15, C17, C27, U30, A35, A39, 
and C50.
Upon folding the 3018-3159 (3-globin RNA using the Mfold program (Zuker, 2003), only 
one structure was in close agreement with the experimental data (Figure 2.11a). The 
experimental data were then used a constraint in conjunction with the structure generated by 
Mfold to obtain the experimental structure shown in Figure 2.11b. The determined structure 
consists of 7 stems, 6  internal bulges, 2 hairpin loops, and 1 multibranched loop. Stems II, 
III, and VI consist of two base pairs, while stems I, IV, V, VII consist of three, six, five, and 
three base-pairs, respectively. Four of the stems in the determined structure were also present 
in the stmcture generated by Mfold and include: stems I, II, III, V, and VI. In addition, stems 
rv  and VII were also present in the structure generated by Mfold, except that that some base- 
pairs were eliminated or added. There is also a large internal loop located between stems VI 
and VII and the large multi-branched loop surrounding stems IV, V, and VI. The 
experimental structure shown in Figure 2.12 consists of a summary of the cleavage sites 
generated at each position cleaved by the particular RNase probe.
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Figure 2.10. Structure probing of the 5’ end-labeled P-globin RNA corresponding to 
nucleotides 3018-3159 on a 12% polyacrylamide/7M urea gel. The samples were run for 2 
hours (a) and 4 hours (b), fixed, scanned, and then visualized. Several guanosine residues are 
indicated on the left of the diagram, whereas some of the sites cleaved by RNase A are 
indicated on the right of the diagram. Brackets 1 and 2 indicate the two laddering regions 
generated by RNase V 1.
54
b)
A U 
S O C — G
C — G  Stem  V II
A — U
G
C C 60U
G A G G
A 70
C
A
G
A
^A
C
U
c
cu
G
A 70
90
Y ?? ‘r'î "
A
Stem  VI
U C j^SO
G
C
C
G
U
A"
Stem  V ,
c c
30 u — G 
C — G 
A—  U 
C — G 
U —— A 
U— A
90
y
A C G G d  
A 100
G
U
Stem  IV
U
20 C-
€  110
G
U
G
-G
A
A — U 
C — G
Stem III
A
AC—G 120 
A— U Stem II
G U
A 130
U
10 u
u
c
G
A C A U U U
C — G
G 
G 
U 
G 
A 130
G A ^
140 C — G
G — C Stem  I
G — C 
G C 
U
Figure 2.11. The secondary structure of the P-glohin RNA corresponding to nucleotides 
3018-3159. The structure determined hy Mfold (a) was used in conjunction with the prohing 
data to obtain a consensus structure (b).
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Figure 2.12. Secondary structure model for the 3018-3159 (3-globin RNA showing locations 
of bases accessible for enzyme probes. This secondary structure was obtained by using the 
probing data as constraint with the Mfold program (Zuker, 2003). Hatched and open symbols 
represent moderate and weak cleavage, respectively, while filled symbols represent strong 
modification. RNase VI cleavage sites are indicated by arrow intensity. D and N indicate 
cleavage with RNase T l under RNA denaturing or native conditions, respectively.
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2.2 Discussion 
c-m\c CRD nts 1705-1792
Cleavage of the 1705-1792 end-labeled CRD transcript with RNase T l under RNA 
denaturing condition generated several bands corresponding to guanosine residues. The lack 
of a 1705-1792 intact CRD RNA (lane 3, Figure 2.7) might be due to the partial loss of the 
RNA during ethanol precipitation or due to the higher RNase T l activity on the denatured 
RNA. These partial digestion conditions were used in subsequent experiments, where it was 
clearly shown that the cleavage sites generated were the result of partial digestion, rather than 
complete digestion.
Digestion of the 5’ end-labeled transcript with RNase T l under both denaturing and native 
conditions is essential in order to gain insights into the nature of the strandedness of the 
guanosine residues (Ehresmann et ah, 1987). The presence of a guanosine cleavage site upon 
RNase T l digestion under both RNA denaturing and native conditions would indicate that 
the guanosine residue remains single-stranded upon refolding (Ehresmann et al., 1987). The 
cleavage of guanosine residues: 1731, 1749, and 1770 by RNase T l under both RNA 
denaturing and native conditions indicates their localization in a single-stranded domain. The 
presence of a guanosine cleavage site generated by RNase T l under denaturing conditions 
and its disappearance under native conditions, indicates that the guanosine residue is present 
in a double-stranded region. This is observed with G1745, G1746, and G1764, indicating 
that these guanosine residues are present in a stem region. The presence of a more intense 
cleavage site upon RNase T l cleavage under RNA native conditions compared to denaturing 
conditions, indicates the localization of the guanosine residue in a single-stranded region that 
is relatively highly accessible by RNase T l. This finding was observed with G 1749 and
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G1770, however, due to the difference in input RNA loaded between the native and 
denaturing conditions, such correlation cannot be made in this case.
RNase T2 prefers to cleave 3’ to single-stranded adenosine residues (Ehresmann et al., 
1987). However, it is also capable of cleaving 3’ to U, G, and C residues present in single­
stranded domains (Ehresmann et al., 1987; Walker and Avis, 2005). The cleavage of the two 
RNase Tl-cleaved residues, G 1749 and G1770, by RNase T2 and the lack of cleavage of 
these sites by the double-strand specific enzyme, RNase V I, confirms the single­
strandedness of these guanosine residues. Eurthermore, the ability of RNase T2 to cleave 3’ 
to any single-stranded nucleotide explains why residues that were cleaved by RNase A were 
also cleaved by RNase T2. The intense cleavage generated by RNase T2 3’ to nucleotide 
1748 and the absence of cleavage at this site by RNase VI indicates that this adenosine 
residue is present in a highly accessible single-stranded region. Furthermore, the presence of 
a cleavage 3’ to A1758 by RNase T2 and the absence of cleavage at this site by RNase VI 
indicates the single-strandedness of this residue. The nucleotides involved in the two RNase 
VI laddering regions, namely the regions consisting of nts 1721-1724 and nts 1727-1734, 
were also cleaved by RNase T2. Cleavage 3’ to nucleotide C1727 was also observed by 
RNase A. Therefore, the cleavage by both RNase T2 and RNase VI of nucleotides 1721- 
1723 and 1729-1731, which comprise stems II and III, respectively, indicate that these two 
stems are unstable, possibly due to the “breathing” of this dynamic structure that results in 
the generation of two alternative structures, an entirely open structure and a double-stranded 
structure. The dynamic nature of stem III is further confirmed by cleavage 3’ to nucleotides 
C1771 and U1773 by both the single-strand specific enzymes, RNase T2 and RNase A and 
the double-strand specific enzyme, RNase V I. RNase VI is also known to be capable of
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cleaving some stacked unpaired bases (Ehresmann et al., 1987; Lowman and Draper, 1986). 
Such cleavage hy RNase VI might he the case for nucleotides 1724, 1727, 1728, 1732, 1733, 
1734, and 1768, which span single-stranded regions in proximity to stems II, III and IV, 
therefore allowing the stacking of these hases. The observation that nucleotides 1747-1752 
were cleaved hy the single-stranded specific enzyme, RNase T2, and not hy RNase V I, 
indicates with high confidence that this laddering region is single-stranded. Stem V was also 
found to he unstable, based on cleavage hy RNase T2 and RNase VI of similar sites within 
this stem. Evidence for the existence of this stem is based on the cleavage 3’ to nucleotides 
1743-1745 and 1754-1757 hy RNase VI and the lack of cleavage 3’ to G1745 hy RNase T l 
under RNA native conditions. The dynamic nature of stem V is deduced based on cleavage 
within this stem hy RNase T2 of the three sites that were cleaved hy RNase V I, A1743, 
A 1744, and U1757. The instability of stem V might he due to the “breathing” of the AU 
hase-pairs within this stem, which allows cleavage hy RNase T2. The results discussed, 
therefore, point to an overall unstable and dynamic secondary structure. However in vivo, this 
structure could he stabilized hy RNA-hinding proteins and/or divalent cations, which may 
allow such an unstable structure to exist.
Mfold analysis on the full-length c-myc CRD RNA (1705-1886) (Figure 2.13) and the 
full-length c-myc mRNA (Figure 2.14) was performed to gain an insight into the folding of 
the 1705-1792 CRD region within these RNAs. The most energetically-favorahle secondary 
structures of both RNAs were chosen and it was shown that stems IV and V were conserved 
between these two RNAs. It is likely, therefore, that both stems IV and V are also conserved 
in vivo. In addition, the full-length CRD RNA structure has a Tm value of 63.4°C, while the 
full-length c-myc mRNA structure has a Tm value of 74°C. These values are greater than
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room temperature, indicating that both of these structures are likely to be stable and non­
dynamic at room temperature. This enhances the likeliness that the two conserved stems exist 
within c-myc mRNA in vitro and in vivo.
It is essential to point out that the in v/tro-transcribed 1705-1792 CRD RNA contains five 
nucleotides that belong to the EcoRI restriction site (GAATT). These five nucleotides, 
however, were not included in the determined secondary structure. Upon Mfold analysis of 
the 1705-1792 c-myc CRD RNA with the presence of the five nucleotides, the CRD structure 
was identical to the determined secondary structure, as the five nucleotides were not involved 
in any base-pairing interactions (data not shown). Therefore, this validates the cleavage 
specificity characterization of the novel endonuclease on the presented secondary structure of 
nts 1705-1792 of the c-myc CRD RNA.
In order to investigate whether the determined secondary structure is evolutionarily- 
conserved, phylogenetic RNA analysis was performed by comparing the human 1705-1792 
c-myc CRD region with those of the rat (Rattus norvégiens), mouse {Peromyscus leucopus), 
cat {Felis catus), and cow (Bos taurus) (Figure 2.15). The baboon (Papio hamadryas) and 
chimpanzee (Pan troglodytes) CRD sequences are 100% homologous to the human c-myc 
CRD region and, therefore, were not included in this analysis. The alignment of the 
sequences revealed that most of the nucleotides were conserved between these species, 
except for the following variable sites: 1730, 1769, 1772, and 1785. None of these variable 
sites, however, appear to covary with each other, indicating their lack of involvement in an 
evolutionary conserved secondary structure. A detailed alignment analysis is needed to reveal 
with high certainty those sites that covary with each other, and therefore play important roles 
in secondary structure formation.
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Upon folding of these homologous RNA sequences using the Mfold software program, 
variable secondary structures were obtained (Figure 2.16). None of these structures, however, 
were identical to the human 1705-1792 CRD structure, indicating the lack of an evolutionary 
conserved secondary structure between these species in the 1705-1792 CRD region. 
However, six of the residues that are thought to localize within double-stranded domains 
within the human 1705-1792 CRD region are also localized in double-stranded regions in the 
four secondary structures. These nucleotides include; G1721, G1722, G1745, G1746, G1764, 
and C1765 (underlined in Figure 2.16). Therefore, it is likely that these nucleotides are 
double-stranded in the human CRD region, hence, supporting the experimental probing 
results.
The existence of an in vivo secondary structure that is different from the one obtained in 
vitro cannot be excluded (Thisted et ak, 1995), which is mainly due to the presence of RNA- 
binding proteins and cations. RNA-binding proteins are thought to bind secondary structural 
features such as the hairpin, bulge, and internal loops (Richardson et al., 1998). CRD-BP is 
an RNA binding protein implicated in CRD binding (Prokipcak et al., 1994) and may interact 
with the secondary structural features to promote a conformational change in vivo. Such a 
conformational change may also arise due to the presence of ribosomes and endonucleases 
that have also been implicated in c-myc mRNA metabolism. In addition to RNA-binding 
proteins, divalent and monovalent cations are also thought to induce RNA structural 
conformational changes (Batey et ak, 1999; Shiman and Draper, 2000). Monovalent and 
divalent cations (particularly magnesium) interact with the negatively-charged phosphate 
backbone, thereby inducing a third level of RNA organization termed the tertiary structure 
(Shiman and Draper, 2000). Now that the in vitro secondary structure of the 1705-1792 CRD
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region has been determined, one can assess the sequence and structure cleavage specificity of 
the mammalian endoribonuclease.
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Figure 2.13. The 1705-1886 c-myc CRD RNA structure generated by the Mfold software 
program.
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Figure 2.14. The secondary structure of the full-length c-myc mRNA generated by the Mfold 
software program. A, represents the condensed secondary structure of the c-myc mRNA. The 
circled region indicates the 1705-1792 CRD region. B, represents a lOX magnification of the 
circled region.
63
1710 1720 1730 1740
Human ACCAGATCCCGGAGT TGGAAAACAATGAAA AGGCCCCCAAGGTAG 
Rat ACCAGATCCCTGAGT TGGAAAACAACGAAA AGGCCCCCAAGGTAG 
Mouse ACCAGATCCCGGAGT TGGAAAACAATGAAA AGGCCCCCAAGGTAG 
Cat ACCAGATCCCAGAGT TGGAAAACAACGAAA AGGCCCCCAAGGTGG 
Cow ACCAGATCCCAGAGT TGGAGAACAATGAAA AAGCCCCCAAGGTAG
1750 1760 1770 1780 1790
Human TTATCCTTAAAAAAG CCACAGCATACATCC TGTCCGTCCAAGC 
Rat TTATCCTCAAAAAAG CCACCGCCTACATCC TGTCCGTCCAAGC 
Mouse TTATCCTCAAAAAAG CCACCGCCTACATCC TGTCCATCCAAGC 
Cat TGATCCTTAAAAAAG CCACCGCCTACATCC TGTCCGTCCAAGC 
Cow TTATCCTTAAAAAAG CCACAGCGTACATCC TGTCGGTCCAAGC
Figure 2.15. Sequenee alignment of the human 1705-1792 c-myc CRD DNA with the CRD 
sequences present in rat, mouse, eat, and cow using the BCM Search Launcher (Smith et ah, 
1996). Bold letters correspond to the numbering above. The accession numbers for the CRD 
sequences are as follows: human, V00568; rat, Y00396; mouse, AY294987; cat, M15078; 
cow, AF519455.
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Figure 2.16. Comparison between the human 1705-1792 CRD RNA secondary structure 
with those structures generated by Mfold (Zuker, 2003) for a) cat, b) mouse, c) rat, and d) 
cow. Underlined nucleotides indicate residues that were double-stranded in the human CRD 
and remained double-stranded in the secondary structures of all four species.
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B-globin nts 3018-3159
Upon cleavage of the P-globin nts 3018-3159 RNA with RNase T1 under RNA- 
denaturing conditions, sixteen cleavage sites were generated. Fourteen of these cleavage sites 
were also obtained upon cleavage by RNase T1 under RNA native conditions including: G7,
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G13, G22, G24, G32, G45, G62, G69, G71, G72, G74, G77, G81, and G84. The cleavage of 
these sites by RNase T 1 under both RNA native and denaturing conditions indicate that these 
sites are localized within single-stranded domains. The lack of cleavage at G53 and G54 by 
RNase T1 under RNA native conditions indicates the inaccessibility of these sites for 
cleavage, and hence their presence in double-stranded domains. The intense cleavage at G81 
by RNase T1 under native conditions in comparison with RNA denaturing conditions 
indicates that this site is present in a highly accessible region in the secondary structure. 
Upon cleavage with RNase T2, a laddering region is observed between nucleotides 1-12. 
Some of the nucleotides cleaved within this ladder were also cleaved by RNase V 1 including 
A l, C2, A3, U4, U6 , UlO, Cl l ,  and U 12. Cleavage of nucleotides 1-6 by RNase VI might be 
due to the proximity of these nucleotides to a stem-rich area, which allows base-stacking to 
occur. The localization of nucleotides 1-6 in a single-stranded region is further highlighted by 
the intense cleavage at C2 by RNase A and the cleavage by RNase A of the following sites: 
U4, U5, and U6 . The lack of cleavage by RNase VI and the presence of cleavage by RNase 
T2 3’ to nucleotides 7-9, indicates the localization of these nucleotides in a single-stranded 
domain. Cleavage 3’ to nucleotides UlO, Cl l ,  and U12 by RNase VI and the single-strand 
specific enzymes RNase T2 and RNase A, indicates their presence in a dynamic structure 
that can alternate between open and double-stranded conformations. This dynamic structure 
also includes G13, which is cleaved by RNase T1 under both RNA denaturing and native 
conditions and by the double-strand specific enzyme, RNase VI. Overall, this indicates that 
nucleotides 11-13 may be part of stem II and that cleavage of these sites by the RNA single- 
strand specific enzymes is most likely due to the presence of the unstable G-U base-pairs that 
may form between U I2 and G 123, GI3 and UI22. The presence of the two non Watson-
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Crick base-pairings may allow breathing of the stem, and hence accessibility of these sites by 
the RNA single-strand specific enzymes. Nucleotides A18, A19, and C20 were only cleaved 
by the single-strand specific enzyme, RNase T2, indicating their single-stranded localization. 
Furthermore, the third RNase T2 laddering region, encompassing nucleotides 39-44, also 
lacked RNase VI cleavage and two nucleotides within this ladder were also cleaved by 
RNase A, including C39 and C43. Exception to this includes cleavage at C39 by RNase V I, 
which might be due to the stacking of this base. Cleavage by RNase V 1 and RNase A also 
occurred at several positions including C15, C17, C27, U30, and C50. Cleavage 3’ to C17 
and C27 by both enzymes is most likely due to the breathing of the unstable AU base-pairs in 
the respective stems, thereby, allowing access for RNase A to cleave its target sequence. 
RNase A and RNase VI cleavage at C15, U30, and C50 occurred at stem-loop junctions. 
RNase VI is capable of cleaving at these sites due to their involvement in base-pair 
formation. However, it is also feasible for single-strand specific enzymes to cleave at such 
Junctions as there is less steric hindrance in this region in comparison with a nucleotide that 
has a double-stranded 3’ neighboring nucleotide.
Overall, the p-globin RNA nts 3018-3159 is an unstable and a dynamic structure. The 
instability of this structure is mainly the due to the large internal and multi-branch loops, 
which increase the free-energy of formation of the structure. Furthermore, the dynamic 
nature of this structure is also a consequence of the breathing of the weak A-U and G-U base 
pairs, which allows the structure to form alternate secondary stmctures. This stmcture is most 
likely stabilized in vivo by the binding of proteins or through electrostatic interactions with 
the negatively-charged phosphate backbone. Therefore, these two types of interactions may 
allow for the stabilization of the 3018-3159 (3-globin mRNA secondary structure in vivo.
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Chapter 3 
Sequence and Structure Cleavage Specificity of the Novel Mammalian 
Endoribonuclease
The research described in this chapter was conducted to understand the sequenee and 
structural cleavage specificities of the 1705-1792 c-myc CRD region by the novel 
mammalian endoribonuclease. It was also intended that the research would confirm the 
sequence and structural specificity of the enzyme using another in v/tro-transcribed RNA 
substrate, namely, p-globin RNA corresponding to nts 3018-3159. Further confirmation of 
the sequence and structural specificity of the enzyme to the 1705-1792 CRD region was 
obtained by generating a series of mutants encompassing the 1705-1792 CRD region. 
Understanding the sequence and structural RNA cleavage specificity of the 
endoribonuclease, in vitro, is expected to provide insight into the sequence and structural 
cleavage specificity of the enzyme in cells.
3.0 Methods
3.0.1 The endoribonuclease assay and the identification of cleavage products
The 5’ end-labeled 1705-1792 CRD and the 3018-3159 P-globin RNAs (usually 1-3 pi 
containing -30,000 cpm) were incubated with 2 pi (-1-3 units) of the purified 
endoribonuclease, 18 pi reaetion mix and made up to 25 pi with sterile water. Prior to 
ineubation with the endonuelease, the RNA substrate was heated at 50-55*^C for 5 minutes 
and allowed to refold at room temperature for 10 minutes. The reaction mix contained IM 
Tris pH 7.4 (2.8 pi), 100 mM DTT (5.6pl), 100 mM MgOAc (5.6 pi), 4M KOAc (3.5 pi), 2.5 
mM spermidine (11.2 pi), 40 U/pl RNasin (4 pi), and made up to 252 pi with DEPC-H2O. 
However, only 18 pi of reaction mix was required per reaction. Incubation was performed at
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37°C for 5 minutes and was terminated by the addition of 1 |0,1 of phenol. The final volume 
was then made up to 200 pi with DEPC-H2 O, followed by standard ethanol precipitation and 
resuspension of the RNA pellet in 9M urea/phenol loading dye to give final counts of 15,000 
cpm/pl. Two microlitres were loaded onto the gel for visualization. The negative control (not 
treated with the endoribonuclease) was done under the same conditions except that 2  pi of 
sterile water was added instead of the purified endonuclease or nothing was added. The 
cleavage products were identified by running the samples parallel to an alkaline ladder and a 
partial RNase T1 digest under the RNA denaturing condition (as described in section 2.0.3). 
The samples were then loaded and run onto a 12% polyacrylamide/7M urea gel and 
visualized as described in section 2.0.3.
3.0.2 Site-directed mutagenesis for the generation of the 1705-1792 CRD mutants
In order to determine the sequence and structure cleavage specificity of the mammalian 
endoribonuclease to the 1705-1792 c-myc CRD region, sequence and structural mutations 
were generated within the 1705-1792 CRD transcript. The mutations that were generated to 
investigate the sequence specificity of the endonuclease involved generating point mutations 
within the sites that were cleaved by the endoribonuclease or generating potentially new 
cleavage sites without altering the structural features of the RNA. Structural mutations were 
generated by collapsing cleavage sites present in a hairpin-loop into a double-stranded 
conformation or generating potentially new cleavage sites within a double-stranded region. 
The 1705-1792 CRD mutants were generated by designed primers (QIAGEN, Mississauga, 
ON), containing the mutations of interest. The forward primers consisted of (5’ to 3’): 
BamWl restriction site, SP6  polymerase promoter, and wild-type or mutated CRD sequences. 
The reverse primers consisted of (5’ to 3’): EcoRl restriction site and wild-type or mutated
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CRD sequences. Twelve mutants were generated in total, ten of which were designed to test 
the sequence specificity of the endonuclease. The remaining mutants were designed to 
examine the structure specificity of the endoribonuclease to the 1705-1792 CRD RNA.
The CRD mutants designed to determine the RNA sequence specificity of the 
endonuclease include CP-2, CP-3, CP-IOC, CP-IOG, CP-lOU, CP-13, CP-15, CP-19A, CP- 
19G, and CP-19U. These mutants were generated using the primers shown in Table 3.1. The 
CP-2 and CP-3 CRD mutants were designed to test the specificity of the endonuclease to UA 
dinucleotides. The CP-2 CRD mutant involves altering the 1751 uridine residue into an 
adenosine residue and the 1752 adenosine residue into a uridine residue, thereby, converting 
the 1751 UA cleavage site into an AU site. The CP-3 CRD mutant focused on another UA 
site cleaved by the endonuclease (1757 UA), and it involved mutating the uridine at position 
1757 into an adenosine residue and the 1758 adenosine into uridine, thereby, generating an 
AU dinucleotide. The CP-IOC, CP-IOG, and CP-lOU CRD mutants were also designed to 
test the specificity of the endonuclease to UA dinucleotides. These mutants involved 
mutating the 1751 UA cleavage site into UC (CP-IOC), UG (CP-IOG), and UU (CP-lOU) 
dinucleotides.
The CP-13 CRD mutant was designed to examine the specificity of the endoribonuclease 
to UG dinucleotides. This mutant involved mutating the 1730 uridines residue into a 
guanosine residue and the 1731 guanosine residue into a uridine residue, thereby, generating 
a GU dinucleotide.
Four mutants were generated to examine the specificity of the endonuclease to CA 
dinucleotides. The CP-15 CRD mutant involved mutating the cytidine at position 1727 into 
an adenosine and the adenosine at position 1728 into a cytidine, thereby, generating a 1727
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AC dinucleotide. The CP-19A, CP-19G, and CP-19U CRD mutants involved mutating the 
cytidine residue at position 1727 into A, G, and U, respectively, thereby generating the 
following dinucleotides; 1727 AA (CP-19A), 1727 GA (CP-19G), and 1727 UA (CP-19U). 
In order to confirm the absence of any structural alterations in the ten CRD mutants, the 
mutants were folded using the Mfold software program (Zuker, 2003).
Two mutants were generated to investigate the structure specificity of the mammalian 
endonuclease to the 1705-1792 CRD RNA. The two primers used to generate the two 
structural mutants (CP-22 and CP-24) are shown in Table 3.1. The CP-22 CRD mutant 
involves altering the adenosine at position 1743 into a uridine residue and the uridine at 
position 1757 into an adenosine residue. These point mutations generate two additional UA 
dinucleotides at positions 1743 and 1756 that are localized within a double-stranded domain. 
The CP-24 CRD mutant involved mutating the adenosine at position 1752 into a uridine and 
the uridine at position 1753 into an adenosine, thereby allowing for the collapse of the 
hairpin loop and placing the 1747 UA endonuclease cleavage site into a double-stranded 
conformation. The presence of the target structural alterations within the two mutants was 
examined by folding the mutant RNAs using the Mfold program and probing the two 
structure mutants with RNase A. The RNase A reaction conditions were identical to the 
conditions described in section 2.0.3.
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Table 3.1. The 1705-1792 CRD mutants designed for probing the sequence and structure specificity of the novel mammalian endonuclease
CRD
mutant
Mutation Sequence of forward primer* Seqnence of reverse primer^ RNA sequence*
CP-2 U n S l A a n d
A1752U
FUP: 5’- CTCGGATCCATTTAGG 
TGACACTATAGACCAGATCCCG 
GAGTTGG-3’
RCP-2: 5’- CTCGAATTCGCTTGGAC 
GGACAGGATGTATGCTGTGGCTTT 
TTTAAGGAat ACT-3’
5 ’ - ACC AGAUCCCGGAGUUGG AAA 
ACAAUGAAAAGGCCCCCAAGGUA 
GUAUUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-3 U 1757A and 
A1758U
FUP RCP-3: 5 -CTCGAATTCGCTTGGAC 
GGACAGGATGTATGCTGTGGCTTT 
TTTAAGG ATAACatCCT-3 ’
5 -ACCAGAUCCCGGAGUUGGAAA
ACAAUGAAAAGGCCCCCAAGGUA 
GUUAUCCUAUAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-IOG A1752G FUP RCP-IOG: 5 ’ -CTCGAATTCGCTTGG 
ACGGACAGGATGTATGCTGTGGC
5 -ACCAGAUCCCGGAGUUGGAAA 
ACAAUGAAAAGGCCCCCAAGGUA 
GUUGUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-IOC A1752C FUP RCP-1OC : 5 ’ -CTCGAATTCGCTTGGA 
CGGACAGGATGTATGCTGTGGCTT 
TTTTAAGGAgAAC-3’
5 ’ - ACCAGAUCCCGGAGUUGGAAA 
ACAAUGAAAAGGCCCCCAAGGUA 
GUUGUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-lOU A1752U FUP RCP-10U:5 ’ -CTCGAATTCGCTTGGA 
CGGACAGGATGTATGCTGTGGCTT 
TTTTAAGGAaAAC-3’
5’ ACCAGAUCCCGGAGUUGGAAA 
ACAAUGAAAAGGCCCCCAAGGUA 
GUUGUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-13 U1730G
andG1731U
FCP-13: 5 '-CTCGGATCCATTTAG 
GTGACACTATAGACCAGATCCC 
GGAGTTGGAAAACAAgtAAA-3 ’
RUP:5 ’ -CTCGAATTCGCTTGGACG 
GACAGGATGTATGC-3 ’
5 ’ - ACCAGAUCCCGGAGUUGGAAA 
ACAAGUAAAAGGCCCCCAAGGUA 
GUUAUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-15 C l727A and 
A1728C
FCP-15:5-CTCGGATCCATTTAG 
GTGACACTATAGACCAGATCC 
CGG AGTTGG A A AAac ATG-3 ’
RUP 5 ’ - ACCAGAUCCCGGAGUUGGAAA 
AACAUGAAAAGGCCCCCAAGGUA 
GUUAUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-190 C1727G FCP-19G:5’ -CTCGGATCC ATTTA 
GGTGACACTATAGACCAGATC 
CCGG AGTTGGAAAAg AAT-3 ’
RUP 5 ’ - ACCAGAUCCCGGAGUUGGAAA 
ACAAUGAAAAGGCCCCCAAGGUA 
GUUAUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
74
CP-19U C1727U FCP-19U:5 ’ -CTCGGATCC ATTTA 
GGTGACACTATAGACCAGATC 
CCGG AGTTGGAAAAt AAT-3 ’
RUP 5 -ACCAGAUCCCGGAGUUGGAAA
AUAAUGAAAAGGCCCCCAAGGUA 
GUUAUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-19A C l 727A FCP-19 A: 5 ’ -CTCGGATCC ATTTA
GGTGACACTATAGACCAGATC
CCGGAGTTGGAAAAaAAT-3’
RUP 5 ’ - ACCAGAUCCCGGAGUUGGAAA 
AAAAUGAAAAGGCCCCCAAGGUA 
GUUAUCCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-22 A1743U and 
U1757A
FUP RCP-22: 5 ’-CTCGAATTCGCTTGGA 
CGGACAGGATGTATGCTGTGGCTT 
TTTTtAGGATAACTACCTaGGG-3 ’
5 ’ - ACCAGAUCCCGGAGUUGGAAA 
ACAAUGAAAAGGCCCCCUAGGUA 
GUUAUCCUAAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
CP-24 A1752U and 
U1753A
FUP RCP-24; 5’-CTCGAATTCGCTTGGA 
CGGACAGGATGTATGCTGTGGCTT 
TTTTAAGGtaAAC- 3 ’
5 -ACCAGAUCCCGGAGUUGGAAA 
ACAAUGAAAAGGCCCCCAAGGUA 
GUUUACCUUAAAAAAGCCACAGC 
AUACAUCCUGUCCGUCCAAGC-3 ’
1. Bold letters indicate Bam Hl restriction site and small letters indicate mutant residues.
2. Bold letters indicate EcoRI restriction site and small letters indicate mutant residues.
3. Underlined letters indicate mutation sites.
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3.0.3 PCR amplification, digestion, subcloning, and ligation
The plasmid construct containing the wild-type (WT) 1705-1792 cDNA (pUC19-myc 
1705-1792) was used as a template for Polymerase Chain Reaction (PCR) to generate 
products containing the target CRD mutations. The PCR products (5 PCR replicates per 
mutant) were then cleaved with BamRl and EcoRl and suhcloned into a pUC19 plasmid cut 
with BamYil and EcoRI. The PCR reaction consisted of the pUC19-myc 1705-1792 template 
(2 ng), 1 |il of the forward primer (100 ng/(tl), 1 jil of the reverse primer (100 ng/|al), 3.5 |il 
of the lOX PCR buffer (New England Biolabs, Beverly, MA), 3.5 )il of dNTPs (2.5 mM, also 
containing 50 mM MgCE), 0.5 jil of Taq Polymerase (5 U/jal) (New England Biolabs, 
Ontario), and made up to 35 |il with sterile water. The PCR products were then generated 
using the Minicycler™ Peltier Thermal Cycler (MJ Research, Inc., Reno, NV) using the 
following steps; step 1, template dénaturation at 94°C for 30 seconds; step 2, primer 
annealing at 50°C for 30 seconds; step 3, primer extension at 72°C for 45 seconds; step 5, 
repeating the above steps for 29 additional cycles. The five PCR products were then pooled 
together, ethanol precipitated, resuspended in 10 |al gel-loading dye (0.02% w/v 
bromophenol blue, 0.02% w/v xylene cyanol), and loaded onto a 2% agarose gel for gel- 
purification. The gel was run at 35 mA in 0.5X TBE buffer for one hour. The PCR products 
were then gel-purified using the QIAEX II Gel Extraction Kit (Qiagen, Montreal). Gel- 
purification involved resuspending the gel containing the PCR products with three volumes 
(typically -0.5 ml) of Buffer QXl (contents not listed in QIAEX protocol), which functions 
to solubilize the gel, leading to the elution of the PCR products (Qiagen, 1999). This is 
followed by the addition of 20 |ll of the QIAEX II resin (contains a highly electrolytic 
environment which allows DNA adsorption), and then incubation at 50°C for 10 minutes
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with frequent vortexing to allow for resin suspension. The solution was then centrifuged for 
30 seconds at 13,000 rpm to precipitate the resin and the supernatant was removed. The resin 
pellet was then washed with 500 fxl of Buffer QXl and resuspended by vortexing, followed 
by centrifugation at 13,000 rpm for 30 seconds and removal of all traces of the supernatant. 
This washing step functions to remove residual salt contaminants that may later interfere 
with restriction digestion (according to the manufacturer's instructions). The pellet was then 
washed twice with 500 |il of Buffer PE (contents not described in protocol), which contains 
ethanol and efficiently removes salt contaminants (according to the manufacturer's 
instructions). This involved resuspending the pellet in the washing buffer by vortexing, 
centrifugation at 13,000 rpm for 30 seconds, and then removing all traces of the buffer. The 
washed pellet was then air dried until it became white (-30 minutes), resuspended in 20 pi 
Tris-EDTA buffer, pH 8.0, to allow for DNA elution, followed by incubation for 5 minutes at 
room temperature. The solution was then centrifuged for 30 seconds at 13,000 rpm and the 
supernatant containing the PCR product was transferred into another micro tube. In order to 
increase the PCR product recovery, the above steps involving the elution with 20 pi of Tris- 
EDTA buffer, pH 8.0, were repeated and the supernatant was pooled with the previously 
eluted DNA solution. The pooled DNA was then ethanol precipitated and resuspended in 10 
pi sterile water in preparation for restriction digestion. The PCR product (10 pi) was then 
digested with 3 pi of BamYil (10 U/pl) (Invitrogen Life Technologies, Ontario), 3 pi of 
EcoKl (10 U/pl) (Invitrogen Life Technologies, Ontario), 2 pi of lOX React 3 Buffer, and 
made up to 20 pi with sterile water. Digestion of the PCR product was done for 3 hours at 
3 7 '^ C, followed by standard ethanol precipitation, and resuspension in 21 pi sterile water in 
preparation for subcloning into the pUC19 plasmid. The pUC19 digestion was performed in a
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20 |L il final volume containing 3.7 |U,g of the plasmid, 4 |Ltl of BamYil (10 U/|il), 4 |al of EcoRl 
(10 U/|ll), 2 jll of lOX React 3, and made up to 20 pi with sterile water. Incubation was done 
for three hours at 37°C, followed by standard chloroform/phenol extraction, standard ethanol 
precipitation, and resuspension in 70 pi sterile water to obtain a final plasmid concentration 
of 50 ng/pl.
The digested PCR product was then subeloned into the linearized pUC19 plasmid. The 
ligation reaction was performed in a 20 pi final volume containing 1 pi of linearized pUC19 
(50 ng/pl), 10.5 pi of the digested PCR product, 2 pi of lOX DNA ligase buffer (New 
England Biolabs, Ontario), and 2 pi (2,000 U/pl) of T4 DNA ligase (New England Biolabs, 
Ontario), and the solution was then made up to 20 pi with sterile water. The ligation reaction 
was then incubated for two hours at room temperature.
3.0.4 Preparation of Competent Cells, transformation, and plating
Preparation of competent D H 5a cells involved the addition of 10 pi of frozen 
D H 5a stock cells to 3 ml of Luria-Bertani (LB) broth and allowing for overnight agitation at 
37°C. Five hundred microlitres of the overnight grown D H 5a cells were then added to 50 ml 
LB broth and allowed to grow until ODôoo= 0.6. The 50 ml broth, containing the bacterial 
cells, was centrifuged at 2,500 rpm for five minutes and the supernatant was removed. The 
cell pellet was then resuspended in 2.5 ml of cold 50 mM CaCli, and the volume was made 
up to 25 ml and stored on ice for 20 minutes. The sample was then centrifuged for five 
minutes at 2,500 rpm, followed by removal of the supernatant, and resuspension in 3.5 ml of 
CaCli. The 3.5 ml solution containing the competent cells was then stored at 4°C.
Transformation of the ligated plasmid into the competent D H 5a cells involved 
transfecting 200 pi of the competent cells with 7.5 pi of the ligation mix in a pre-chilled
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round-bottom flask, followed by thorough mixing and chilling on ice for 30 minutes. The 
sample was then heat-shocked at 42^C for two minutes, followed by the addition of 1 ml LB 
broth and agitation at 37°C for 30 minutes. Two microlitres of IM isopropyl P-D- 
thiogalactoside (IPTG) and 10 |il (20 mg/ml) of bromo-4-chloro-3-indolyl-beta-D- 
galactopyranosie (X-GAL) were then added to the 1 ml LB broth solution, and poured into a 
pre-warmed agar plate containing 0.05 mg/ml ampicillin. The plates containing the cells were 
incubated in an upright position at 37°C for 30 minutes with the lid partly open, followed by 
overnight incubation at 37^C in an inverted position.
3.0.5 Colony selection, plasmid extraction, and checking for the presence of insert
Ten white colonies were picked from the agar plate using a pipette tip and added to 3 ml 
of LB broth (which also had 1.5 fil of 50 mg/ml ampicillin added to it), followed by 
overnight agitation at 31^C. The plasmid was extracted from the bacterial cells using a mini- 
prep procedure, which involved transferring 1.5 ml of the overnight grown cells into a 
microtube, followed by centrifugation at 13,000 rpm for two minutes. The supernatant was 
then removed and the pellet was resuspended in 500 jil STET buffer (O.IM NaCl, 10 mM 
Tris-Cl, pH 8.0, 1 mM EDTA, pH 8.0, 5% Triton X-100) and 10 |ll of 50 mg/ml lysozyme. 
The solution was then boiled for one minute and centrifuged for ten minutes at 13,000 rpm to 
allow for chromosomal DNA precipitation. The chromosomal pellet was removed using a 
sterile toothpick and 500 |al isopropanol was added to the supernatant containing the 
recombinant plasmid, followed by incubation at -20°C for 30 minutes. The sample was then 
centrifuged for ten minutes at 13,000 rpm, followed by the removal of the supernatant, 
washing the pellet with 200 (tl of 70% ethanol, air drying at room temperature for 15 
minutes, and then resuspension of the pellet in 25 |il sterile water. A mini-digest was then
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performed and was run onto a 2% agarose gel to check for the presence of insert. This 
involved incubating 2 jil of the mini-prepped plasmid with 1 jj,l of BamYil (10 U/pl), 1 pi of 
EcoRI (10 U/pl), 2 pi of lOX React 3, and making up the reaction volume to 10 pi with 
sterile water. The reaction was performed at 37°C for 30 minutes, followed by the addition of 
1 pi of RNase A (10 mg/ml) and 1.5 pi of gel-loading dye and running onto a 2% agarose gel 
for 1.5 hours at 45 mA. The sample was run parallel to an undigested mini-prepped plasmid. 
Colonies containing the insert were then stored in 17% glycerol at -80*^C
3.0.6 Plasmid preparation and sequencing of the RNA mutants
In order to obtain a high quantity of recombinant plasmids, the Qiagen Plasmid Midi Kit 
(Qiagen Inc. Mississauga, ON) was used. One hundred and fifty micrcolitres of the colony 
(stored in 17% glycerol) containing the mutant insert was added to 150 ml LB broth to which 
150 pi of 50 mg/ml ampicillin was added, followed by overnight agitation at 37°C. The cells 
were then centrifuged at 6,000 x g for 15 minutes and all traces of the supernatant were 
removed. Four milliliters of Buffer PI (50 mM Tris.Cl pH 8, 10 mM EDTA, 100 pg/ml 
RNase A) were then added to resuspend the cell pellet until no clumps were present. The 
lysis buffer, P2 [200 mM NaOH, 1% SDS (w/v)] was then added (4 ml) to the cell solution 
and mixed thoroughly by gently inverting 4-6 times, followed by incubation for five minutes 
at room temperature. Four milliliters of the pre-chilled P3 Buffer (3.0 M potassium acetate 
pH 5.5) were immediately added to the solution, followed by gentle inverting 4-6 times and 
incubation for 15 minutes on ice. The addition of Buffer P3 allows for enhanced precipitation 
of genomic DNA, proteins, cell debris, and SDS. The sample was then mixed again and 
immediately centrifuged at 20,000 x g at 4°C for 30 minutes. The supernatant containing the 
plasmid was then poured into a new Nalgene tube and centrifuged again at 20,000 x g at 4*^ C
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for 15 minutes. The supernatant was then poured into the QIAGEN-tip 100 (anion-exehange 
resin), which was equilibrated with Buffer QBT [750 mM NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol (v/v), and 0.15% Triton*  ^ X-100 (v/v)]. The Qiagen-tip was then washed two 
times with 10 ml of Buffer QC [1.0 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v)], 
which acts to remove all contaminants in plasmid preparations such as carbohydrates 
(Qiagen, 1999). The plasmid was then eluted with 5 ml Buffer QF [1.25 M NaCl; 50 mM 
Tris.Cl pH 8.5; 15% isopropanol (v/v)] into a sterilized transparent Nalgene tube. The DNA 
was then precipitated by the addition of 4 ml isopropanol and immediately centrifuged for 30 
minutes at 4‘^ C at 15,000 x g. The supernatant was then carefully removed and the DNA 
pellet was then washed with 2 ml of 70% ethanol and centrifuged at 5,000 x g for ten 
minutes. The 70% ethanol was then removed and the pellet was allowed to dry for 30 
minutes. The pellet was then resuspended in 100 pi sterile water, quantified at 260 nm, 
followed by restriction digestion with EcoRI and BamH\, and running of samples onto a 2% 
agarose gel to check for the presence of DNA insert.
3.0.7 In vitro transcription, dephosphorylation, 5 ’ end-labeling, and gel-puriHcation
This was identical to the procedures described in sections 2.0.1 and 2.0.2
3.1 Results
3.1.1 Cleavage sites generated by the mammalian endoribonuclease using the 1705-1792 
c-myc CRD and 3018-3159 P-globin RNAs as substrates. 
CRD nts 1705-1792
Upon incubation of the 1705-1792 CRD RNA substrate with the purified mammalian 
endonuclease for five minutes at 37®C, fourteen cleavage sites were generated (Figure 3.1a 
and b). These sites included intense cleavage at 1727 CA and 1751 UA, and extremely weak 
cleavage at 1740 CC, 1741 CC, 1750 UU and 1766 CA. Moderate cleavage was observed at
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the following dinucleotides: 1730 UG, 1742 CA, 1747 UA, 1757 UA, 1768 CA, 1771 CA, 
1773 UA, and 1775 CA. There are four UA dinucleotides within single-stranded regions in 
the 1705-1792 CRD RNA and all of which were cleaved by the endoribonuclease (Figure 
3.1b). In addition, there are eight CA dinucleotides in the 1705-1792 CRD region, two of 
which, however, were beyond the detection limit of the polyacrylamide gel (CA 
dinucleotides at positions 1707 and 1788). The remaining six CA dinueleotides were all 
cleaved by the endoribonuclease. It is also important to note that five of the CA 
dinucleotides: 1727, 1742, 1766, 1768, 1775 that were cleaved by the endonuelease are 
located within single-stranded regions (Figure 3.1b). Three UG dinucleotides are present 
within the 1705-1792 CRD region. However, two of which were beyond the limits of the gel 
(UG dinucleotides at positions 1720 and 1780). The identifiable UG dinucleotide at position 
1730 (double-stranded) was cleaved by the endoribonuclease (Figure 3.1a and 3.1b). Eleven 
CC dinucleotides are present within the 1705-1792 CRD region, however, only six were 
identifiable within the limits of the gel (1738, 1739, 1740, 1741, 1754, 1765). Two of the 
identifiable CC dinucleotides were weakly cleaved by the endonuclease, including the single- 
stranded dinucleotides at positions 1740 and 1741. Lastly, there are two identifiable UU 
dinucleotides within the 1705-1792 CRD RNA (1750 UU and 1756 UU). Only the single­
stranded UU dinucleotide at position 1750 was cleaved, very weakly, by the endonuclease.
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Figure 3.1. Cleavage sites generated by the mammalian endonuelease using the 1705-1792 
CRD RNA as a substrate. A, the samples were run on a 12% polyacrylamide/7M urea gel 
parallel to an alkaline ladder and an RNase T1 digest for band identification. Numbering on 
the left indicates several guanosine residues cleaved by RNase T l, while bands on the right 
indicate cleavage sites generated by the endonuclease. B, location of the fourteen cleavage 
sites generated by the endonuclease. The cleavage intensity is indicated by the thickness of 
the arrow.
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B-globin nts 3018-3159
Upon incubation of the B-globin 3018-3159 RNA with the endonuclease for 5 minutes at 
37 °C, twenty-two cleavage sites were identifiable on the 12% polyacrylamide/7M urea gel 
(Figures 3.2a and 3.2b). Intense cleavage occurred at the dinucleotides: 2 CA, 39 CA, and 43 
CA, whereas weak cleavage occurred at dinucleotides: 4 UU, 5 UU, 6 UG, 8 CU, 9 UU, 10 
UC, 11 CU, 23 UG, 27 CA, 47 CA, and 52 UG. Moderate cleavage occurred at 
dinucleotides: 12 UG, 15 CA, 17 CA, 20 CU, 21 UG, 30 UA, 33 CA, and 50 CA. There is 
only one UA dinucleotide in the P-glohin 3018-3159 RNA. This dinucleotide (30 UA) is 
present in a single-stranded domain and was cleaved by the mammalian endonuclease 
(Figures 3.2a and 3.2h) Twelve CA dinucleotides are present within the P-glohin 3018-3159 
RNA, however, nine of which were identifiable within the limits of the gel (up to 
dinucleotide 50 CA). The nine identifiable CA dinucleotides were all cleaved by the 
endonuclease (Figures 3.2a and 3.2b). The endonuclease was able to cleave CA dinucleotides 
present within single-stranded (2 CA, 15 CA, 33 CA, 39 CA, 43 CA, 47 CA, 50 CA) and 
double-stranded regions (17 CA, 27 CA). Nineteen UG dinucleotides are present within the 
p-globin 3018-3159 RNA, however, only five were identifiable using the described gel 
electrophoresis conditions. All five dinucleotides were cleaved by the endonuclease and all 
are present within single-stranded domains (6 UG, 12 UG, 21 UG, 23 UG, 52 UG). There are 
six UU dinucleotides within the P-globin 3018-3159 RNA, however, only four were 
detectable using the described conditions of the gel. Three of the four detected UU 
dinucleotides, which are localized in single-stranded domains, were cleaved by the 
endonuclease (4 UU, 5 UU, 9 UU). The double-stranded 25 UU, however, was not cleaved 
by the endonuclease. Lastly, there are five detectable CU dinucleotides within the 3018-3159
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P-globin RNA. The single-stranded dinucleotides: 8 CU, 11 CU, and 20 CU were all cleaved 
by the endonuclease, while none of the double-stranded CU dinucleotides (29 CU and 37 
CU) were cleaved by the endonuclease.
3.1.2 Sequences of the pUC19 plasmids containing the mutant 1705-1792 cDNAs
The pUC19 plasmids containing the mutant 1705-1792 cDNAs were sequenced by the 
DNA Sequencing Laboratory at the University of British Columbia (Vancouver, EC). The 
1705-1792 c-myc plasmid sequences containing the CRD mutants are found in the Appendix 
of this thesis. All of the sequences were as expected, except those corresponding to CP-IOG, 
CP-13 and CP-22. The sequenced CP-IOG CRD mutant (5’- 
ACCAGAUCCCGGAGUUGGAAAACAAUGAAAAGGCCCCCAAGGUAGUUGUCCU 
UAAAAAAGCCACAGAUACAUCCUGUCCGUCCAAGC-3) contained the target 
mutation, however, it lacked the cytidine residue at position 1771. The sequenced CP-13 
CRD mutant (5 ' - ACC AGAUCCCGGAGUUGGAAAACAAGU AAAGGCCCCC AAGGUA 
GUUAUCCUUAAAAAAGCCACAGC AUACAUCCUGUCCGUCCAAGC-3 ’ ) consisted 
of the target mutations: U1730G and G1731U, however, it lacked one of the four adenosine 
residues located between 1732-1734. The sequenced CP-22 (5’-
ACCAGAUCCAGAGUUGGAAAACAAUGAAAAGGCCCCCUAGGUAGUUAUCCUA 
AAAAAAGCCACAGCAUACAUCCUGUCCGUCCAAGC-3’) mutant consisted of the 
target mutations: A1743U and U1757A, however, other mutations were present. The 
mutations included the deletion of 1714C and 1715G and the addition of an adenosine 
residue at position 1714. Although the above three CRD mutants contained unwanted 
mutations, they were also analyzed for understanding the sequence and structure cleavage 
specificity of the mammalian endonuclease.
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Figure 3.2. Cleavage sites generated by the mammalian endonuelease using the P-globin 
3018-3159 RNA as a substrate. A, the samples were run on a 12% polyacrylamide/7M urea 
gel parallel to an alkaline ladder and a partial RNase T l digest for band identification. 
Numbering on the left indicate several guanosine residues cleaved by RNase T l, while 
numbering on the right indicate cleavage sites generated by the endonuelease. B, location of 
the twenty-two cleavage sites generated by the endonuclease. The cleavage intensity is 
indicated by the thickness of the arrow.
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3.1.3 The sequence/structure cleavage specificity of the endoribonuclease to the 
different 1705-1792 CRD RNA mutants. 
Specificity to UA dinucleotides
The CP-2 and CP-3 CRD mutants were designed to examine the specificity of the 
endonuclease to UA dinucleotides. Upon incubation of the CP-2 RNA mutant (1751 UA to 
AU) with the mammalian endonuclease, cleavage at position 1751 was abolished (lane 6 , 
Figure 3.3a). In addition, the endonuclease was able to cleave the newly-generated single­
stranded UA dinueleotide at position 1750 (lane 6 , Figure 3.3a; Figure 3.3b). This cleavage 
was approximately similar in intensity to the cleavage of the 1751 UA dinucleotide in the 
wild-type (WT) 1705-1792 CRD RNA by the endonuclease (compare lane 4 with 6 , Figure 
3.3a). Upon incubation of the CP-3 CRD mutant (1757 UA to AU) with the mammalian 
endonuelease, cleavage at position 1757 was abolished (lane 8 , Figure 3.3a; Figure 3.3c). 
Furthermore, the endonuclease was able to cleave the new single-stranded UA dinucleotide 
at position 1758, in addition to the cleavage of the new 1756 UA dinucleotide present at a 
stem-loop junction. Interestingly, while the intensity of the bands related to the other 
cleavage sites remained unchanged, there was an enhanced band at position 1742 CA, which 
indicates that this dinucleotide became more accessible for enzymatic cleavage. This is 
because it changed from being in a stem-loop junction to a single-stranded domain.
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Figure 3.3. The cleavage of the CP-2 and CP-3 CRD mutants by the endonuclease. A), the 
digested CP-2 and CP-3 CRD mutants were run a 12% polyacrylamide/7M urea gel parallel 
to an alkaline ladder and an RNase T l digest. Numbering on the left indicate several of the 
guanosine residues cleaved by RNase T l, while numbering on the right indicate cleavage 
sites generated by the endonuclease using the WT RNA as a substrate. B) and C) indicate 
cleavage sites generated upon incubation of the CP-2 and CP-3 CRD mutants with the 
endonuclease, respectively. Thick arrows indicate enhanced cleavage, underlined nucleotides 
indicate mutated residues, and the t-shaped symbol indicates blockage of cleavage.
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Upon incubation of the CP-IOC RNA mutant (1751 UA to UC) with the mammalian 
endonuclease, there was a decrease in cleavage at the 1751 dinucleotide (UC dinucleotide) 
(lane 6 , Figure 3.4a; Figure 3.4h) in comparison with the respective WT RNA cleavage (lane 
4, Figure 3.4a). Furthermore, the cleavage intensity at the single-stranded 1751 UC was a 
weak cleavage in comparison with the hands in the same lane. Digestion of the CP-IGG RNA 
mutant (1751 UA to UG) with the mammalian endonuclease, led to a decrease in cleavage at 
the 1751 UG dinucleotide (lane 8 , Figure 3.4a; Figure 3.4c). The absence of cleavage at the 
1771 CA dinucleotide was due to an unintentional deletion of the 1771 cytidine residue. This 
led to the faster migration of the high molecular cleavage sites: 1772 UA and 1774 CA, 
which correspond to WT dinucleotides: 1773 UA and 1775 CA, respectively. Lastly, upon 
incubation of the CP-lOU RNA mutant (1751 UA to UU) with the mammalian endonuclease, 
cleavage at position 1751 was abolished (lane 6 , Figure 3.5a; Figure 3.5b). There was also a 
marked decrease in cleavage at the 1747 UA dinucleotide, which is present in the same 
hairpin loop as the 1751 UU dinucleotide. It is important to note that the discrepancy 
observed between the migration of the WT and CP-lOU RNA bands is due to the unbalanced 
electric current that was run through the gel, rather than the presence of a nucleotide deletion. 
The unbalanced current led to the uneven migration of the CP-lOU RNA samples, hence, the 
observed migration difference between the WT and the CP-lOU cleavage fragments.
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Figure 3.4. The cleavage of the CP-IOC and CP-IOG CRD mutants by the endonuclease. A), 
the digested CP-IOC and CP-IOG were run on a 12% polyacrylamide/7M urea gel parallel to 
an alkaline ladder and an RNase T1 digest. Numbering on the left indicate several of the 
guanosine residues cleaved by RNase T l, while numbering on the right indicate cleavage 
sites generated by the endonuclease using the WT RNA as a substrate. B) and C) indicate 
cleavage sites generated upon incubation of the CP-IOC and CP-IOG with the endonuclease, 
respectively. Dotted arrows indicate decreased cleavage and underlined nucleotides indicate 
mutated residues.
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Figure 3.5. The cleavage of the CP-lOU CRD mutant by the endonuclease. A), the digested 
CP-lOU CRD mutant was run on a 12% polyacrylamide/7M urea gel parallel to an alkaline 
ladder and an RNase T l digest. Numbering on the left indicate several of the guanosine 
residues cleaved by RNase T l, while numbering on the right indicate cleavage sites 
generated by the endonuclease using the WT RNA or CP-lOU (asterisk) as substrates. B) 
indicates cleavage sites generated upon incubation of the CP-lOU CRD mutant with the 
endonuclease. Dotted arrows indicate decreased cleavage, underlined nucleotides indicate 
mutated residues, and the t-shaped symbol indicates blockage of cleavage.
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Specificity to CA dinucleotides
Upon incubation of the CP-15 CRD mutant (1727 CA to AC) with the mammalian 
endonuclease, the cleavage at position 1727 was abolished (lane 6 , Figure 3.6a; Figure 3.6b). 
However, there was cleavage at the newly generated 1728 CA dinucleotide, which is located 
at a stem-loop junction. Digestion of the CP-19A RNA mutant (1727 CA to AA) with the 
mammalian endonuclease led to the disappearance of cleavage at position 1727 (lane 6 , 
Figure 3.7a; Figure 3.7b). In addition, there was an enhanced cleavage at the double-stranded 
1730 UG dinucleotide and a weak cleavage at the 1726 AA dinucleotide. Upon cleavage of 
the CP-19G RNA mutant (1727 CA to GA) with the mammalian endonuclease, cleavage at 
position 1727 was inhibited (lane 8 , Figure 3.7a; Figure 3.7c). Lastly, upon mutating 
dinucleotide 1727 CA to UA (CP-19U), an intense cleavage band was still observed at 
position 1727 (lane 10, Figure 3.7a; Figure 3.7d). This cleavage corresponds to the new 
single-stranded 1727 UA dinucleotide.
Specificity to UG dinucleotides
As indicated in section 3.1.2, the CP-13 CRD mutant lacks one of the four adenosines 
located at position 1732-1734 of the WT 1705-1792 CRD RNA. This is apparent in Figure 
3.8a, where the cleavage fragments (cleavage sites at positions 1741 and above) generated by 
the endonuclease migrated at a faster rate than the corresponding WT fragments and have 
shifted one nucleotide position below the corresponding WT hand. Upon incubation of the 
CP-13 CRD mutant (1730 UG to GU) with the endonuclease, cleavage at position 1730 was 
abolished (lane 5, Figure 3.8a; Figure 3.8b). In addition, an intense cleavage is observed at 
the newly generated single-stranded 1731 UA dinucleotide.
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Figure 3.6. The cleavage of the CP-15 CRD mutant by the endonuclease. A), the digested 
CP-15 was run a 12% polyacrylamide/7M urea gel parallel to an alkaline ladder and an 
RNase T l digest. Numbering on the left indicate several of the guanosine residues cleaved by 
RNase T l, while numbering on the right indicate cleavage sites generated by the 
endonuclease using the WT RNA as a substrate. B) indicates cleavage sites generated upon 
incubation of the CP-15 CRD mutant with endonuclease. The arrow indicates new cleavage 
sites, underlined nucleotides indicate mutated residues, and the t-shaped symbol indicates 
blockage of cleavage.
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Figure 3,7. The cleavage of the three CP-19 CRD mutants hy the endonuclease. A), the 
digested CP-19A, CP-19G, and CP-19U RNA mutants were run a 12% polyacrylamide/7M 
urea gel parallel to an alkaline ladder and an RNase T l digest. Numbering on the left indicate 
several of the guanosine residues cleaved by RNase T l, while numbering on the right 
indicate cleavage sites generated hy the endonuclease using the WT RNA as a substrate. B), 
C), and D) indicate cleavage sites generated upon incubation of the CP-19A, CP-19G, and 
CP-19U, respectively, with the endonuclease. Thick arrows indicate enhanced cleavage, 
underlined nucleotides indicate mutated residues, and the t-shaped symbol indicates blockage 
of cleavage.
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Figure 3.8. The cleavage of the CP-13 CRD mutant by the endonuclease. A), the digested 
CP-13 was run a 12% polyacrylamide/7M urea gel parallel to an alkaline ladder and an 
RNase T l digest. Numbering on the right indicate cleavage sites generated by the 
endonuclease using the WT RNA as a substrate B) indicates cleavage sites generated upon 
incubation of the CP-13 with the endonuclease. Arrow indicates cleavage sites, underlined 
nucleotides indicate mutated residues, and the t-shaped symbol indicates blockage of 
cleavage.
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Structure specificity
As indicated in section 3.1.2, the CP-22 CRD mutant has a deletion of two wild-type 
nucleotides and an addition of a new residue. Overall, this leads to the faster migration of the 
CP-22 cleavage fragments (one nucleotide faster) in comparison with the respective wild- 
type cleavage fragments. The point mutations under investigation are therefore located at 
positions 1742 (1742 A to U) and 1756 (U to A) in the CP-22 CRD mutant. The deletions of 
the 1714 cytosine and 1715 guanosine residues and the addition of an adenosine residue at 
position 1714, may cause the CP-22 CRD mutant to form a different secondary structure than 
that of the wild-type. The likely secondary structure of the CP-22 CRD mutant was 
determined using the Mfold program (Zuker, 2003) in conjunction with the RNase A probing 
data. Digestion of the CP-22 CRD mutant by RNase A generated several identical fragments 
to those generated upon cleavage of the WT 1705-1792 CRD RNA with RNase A (Lanes 3 
and 5, Figure 3.9a). RNase A, however, was also able to cleave at the double-stranded 
dinucleotide, 1742 U. In addition, there was an enhanced cleavage at position 1739 C 
(corresponds to WT 1740 C) and an inhibition of cleavage at position 1756. Overall, the 
probing data is in agreement with the structure determined by the Mfold program (Figure 
3.9b).
Upon incubation of the CP-22 CRD mutant with the endonuclease, there was an intense 
cleavage at the double-stranded 1742 UA dinucleotide and a weak cleavage at the double­
stranded 1755 UA dinucleotide (Lane 5, Figure 3.9c; Figure 3.9d). In addition, there was an 
inhibition of cleavage at position 1756 (corresponds to an AA dinucleotide). Furthermore, 
there was cleavage at the single-stranded 1741 CU and 1722 AA dinucleotides and enhanced 
cleavage at the 1739 CC and 1740 CC dinucleotides.
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The CP-24 CRD mutant (1752 AU to UA) was designed to generate two double-stranded 
UA dinucleotides (1747 UA and 1752 UA) within stem V. To confirm the presence of the 
target secondary structure, the structure of the CP-24 CRD mutant was determined using the 
Mfold program in conjunction with the RNase A probing data (Figure 3.10a). The cleavage 
sites generated by RNase A upon incubation with the CP-24 CRD mutant were similar to 
those generated upon incubation of the WT 1705-1792 CRD RNA with RNase A (lanes 3 
and 5, Figure 3.10a). However, RNase A was also able to weakly cleave the double-stranded 
dinucleotide, 1747 UA. Overall, the RNase A probing data was in agreement with the 
structure generated by Mfold, which indicated the presence of the intended secondary 
structure (Figure 3.10b).
Upon incubation of the CP-24 CRD RNA mutant with the mammalian endonuclease, the 
cleavage at the double-stranded 1747 UA dinucleotide was decreased and there was no 
cleavage at position 1751 (UU) (lane 5, Figure 3.10c; Figure 3.10d). In addition, there was 
cleavage at the new UA 1752 UA dinucleotide, which is located in a double-stranded 
domain. The intensity of cleavage at the 1752 UA dinucleotide was much greater than the 
effect of RNase A, indicating that the endonuclease has a higher affinity for cleaving this site 
than RNase A.
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Figure 3.9. Structure probing of the CP-22 CRD mutant using RNase A and cleavage of the 
CP-22 CRD mutant by the endonuclease. A), CP-22 was digested with RNase A and ran on a 
12% polyacrylamide/7M urea gel parallel to an alkaline ladder and an RNase T l digest. B) 
corresponds to the CP-22 secondary structure including all the RNase A cleavage sites. C) 
indicates the 12% polyacrylamide/VM urea gel containing the endonucleolytically digested 
CP-22 CRD mutant. D) indicates all the cleavage sites generated upon incubation of the CP- 
22 with the endonuclease. Numbering on the left indicates several cleavage sites generated 
by incubating the WT RNA with RNase A or the endonuclease, while numbering on the right 
(*) indicates several cleavage sites generated by incubating the CP-22 CRD mutant with 
RNase A or the endonuclease.
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Figure 3.10. Structure probing o f the CP-24 CRD mutant using RNase A and cleavage o f the 
CP-24 CRD mutant by the endonuclease. A), CP-24 was digested with RNase A and ran on a 
12% polyacrylamide/7M urea gel parallel to an alkaline ladder and an RNase T l digest. B) 
corresponds to the CP-24 secondary structure including all the RNase A cleavage sites C) 
indicates 12% polyacrylamide/7M urea gel containing the endonucleolytically digested CP- 
24 CRD mutant. D) indicates all cleavage sites generated upon incubation of the CP-24 with 
the endonuclease. Numbering on the right indicates several cleavage sites generated by 
RNase A or the endonuclease upon incubation with the WT RNA substrate.
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3.2 Discussion
Overall, the results clearly indicate that one of the sites preferred for cleavage by the 
endonuclease is 3’ to uridines within UA dinucleotides, whether present in single-stranded 
domains or stem-loop junctions. Evidence of this includes the cleavage of all four UA 
dinucleotides present in the 1705-1792 CRD region and the UA dinucleotide within the 
3018-3159 P-globin RNA. Additional evidence stems from several of the 1705-1792 CRD 
mutants including CP-2, CP-3, CP-IOC, CP-IOG, CP-lOU, CP-13, CP-19U, and CP-22. 
Upon mutating the 1751 UA (CP-2) and 1757 UA (CP-3) dinucleotides to AU, cleavage at 
these positions was inhibited. Mutation of the 1752 adenosine residue to C, G, and U (CP- 
lOC, CP-IOG, CP-lOU, respectively) led to a large decrease or inhibition of cleavage at the 
1751 dinucleotide, therefore indicating the importance of the 3’ adenosine residue in 
promoting strong cleavage by the endonuclease at UA dinucleotides. The decrease in 
cleavage at the 1747 UA dinucleotide upon digestion of the CP-lOU CRD mutant by the 
endonuclease maybe due to the presence of a pseudo-knot. This pseudo-knot can potentially 
be generated by base-pairing between the 1750-1753 uridine residues and four of the 
adenosine residues present between stems IV and V (1758-1763). The formation of the 
pseudo-knot displaces stems IV and V and may place them in close proximity to each other 
and to the new UA-rich stem. As a result, the 1747 UA dinucleotide maybe rendered less 
accessible for cleavage by the endonuclease due to the steric hindrance resulting from the 
clustering of the three stems.
Additional evidence for preference of the endonuclease towards cleavage of UA 
dinucleotides includes cleavage of the 1727 UA within the CP-19U CRD mutant. Strong 
cleavage at position 1727 was only prominent upon mutating the 1727 cytidine to uridine.
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therefore, indicating the importance of the uridine residue in promoting cleavage within the 
UA dinucleotide. Lastly, the strong cleavage at the newly generated single-stranded 1731 UA 
dinucleotide in the CP-13 CRD mutant and the inhibition of cleavage at the 1756 
dinucleotide upon mutating 1756 UA to AA (CP-22), provide further evidence for the 
affinity of the endonuclease towards UA dinucleotides.
The endonuclease was also found to be capable of cleaving double-stranded UA 
dinucleotides as evidenced by the CP-22 and CP-24 CRD mutants. The new UA 
dinucleotides at positions 1742 and 1755 within the CP-22 CRD mutant were cleaved by the 
endonuclease and are most likely present in double-stranded conformations. As indicated in 
section 2.2, stem V is highly dynamic due to the breathing of AU base-pairs, which renders 
them accessible for cleavage by single-strand specific RNase probes. Hence, the breathing of 
the AU base-pairs may allow the single-strand specific RNase A to cleave at 1742 U. The 
extremely weak cleavage at the double-stranded 1747 U nucleotide within the CP-24 CRD 
mutant by RNase A may also be explained by the breathing of AU base-pairs within stem V. 
Upon folding the CP-22 structure using the Mfold program, several potential structures were 
obtained, all of which however, show that the 1742 U and 1755 U nucleotides are double­
stranded and are localized in stem V. This is not surprising as this mutation is a conservative 
one that is not expected to alter the RNA secondary structure. The 1747 UA double-stranded 
dinucleotide in the CP-24 CRD mutant was more strongly cleaved by the novel endonuclease 
than by RNase A. The decrease in cleavage at position 1747 UA upon localization within a 
double-stranded domain indicates that the endonuclease preferentially cleaves single­
stranded UA dinucleotides. However, additional mutational experiments need to be
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completed, in which the strandedness of the remaining three UA dinucleotides are rendered 
double-stranded, to confirm such a preference.
In addition to UA dinucleotides, the endonuclease appears to have a preference for 
cleaving 3’ to cytidine residues within CA dinucleotides, regardless of the strandedness of 
the dinucleotide. Evidence includes cleavage of the WT 1705-1792 CRD, 3018-3159 (3- 
globin, CP-15, CP-19A, CP-19G, CP19U, and CP-22 RNAs by the endonuclease. All of the 
CA dinucleotides present in the 1705-1792 CRD and 3018-3159 P-globin RNAs were 
cleaved by the endonuclease, regardless of their localization. The specificity to CA 
dinucleotides is further confirmed by the absence of cleavage at position 1727 within the CP- 
15 CRD mutant. Upon reversing the orientation of the 1727 CA dinucleotide into AC, the 
intense cleavage at this position was completely abolished, indicating that cleavage is only 
induced when the adenosine residue is located 3’ to cytidines. The intense cleavage at the 
1728 CA dinucleotide within the CP-15 CRD mutant, further confirms the affinity towards 
CA dinucleotides. The specificity towards CA dinucleotides by the endonuclease was also 
examined by incubating the endonuclease with the three CP-19 CRD mutants. The intense 
cleavage at the 1727 position was abolished upon mutating the CA dinucleotide into AA or 
GA, therefore, indicating that purines cannot be substituted for cytidines in order for 
cleavage to occur 5’ to adenosines. The enhanced cleavage at 1730 UG within the CP-19A 
CRD mutant can potentially be attributed to an alteration of the tertiary structure of the CRD 
mutant. The alteration in the RNA tertiary structure may position 1730 UG dinucleotide in a 
more accessible conformation for cleavage by the endonuclease. The endonuclease was also 
capable of cleaving double-stranded CA dinucleotides. Evidence of such specificity includes
108
the cleavage of 1771 CA within the 1705-1792 CRD RNA and the 17 CA and 27 CA 
dinucleotides within the 3018-3159 P-globin RNA.
The results indicate that the endonuclease is also capable of cleaving UG 
dinucleotides (3’ to the uridine residue), regardless of their strandedness. The five detected 
single-stranded UG dinucleotides within the 3018-3159 P-globin RNA were all cleaved by 
the endonuclease. These UG residues are either localized in single-stranded regions or stem- 
loop junctions. In addition, upon mutating 1751 UA dinucleotide into UG (CP-IOG), the 
endonuclease was capable of cleaving the single-stranded UG dinucleotide, although with 
less intensity in comparison with the cleavage of the 1751 UA dinucleotide within the WT 
RNA. Further evidence of specificity towards UG dinucleotides includes the complete 
disappearance of cleavage at the 1730 position upon mutating the 1730 UG into GU (CP-13). 
The endonuclease is also capable of cleaving double-stranded UG dinucleotides. Evidence 
includes the cleavage of the double-stranded 1730 UG dinucleotide within the WT 1705- 
1792 CRD region within stem III.
The endonuclease was also capable of cleaving CU dinucleotides (3’ to the cytidine 
dinucleotide) only when present in a single-stranded conformation. There are five CU 
dinucleotides in the 3018-3159 P-globin RNA that are detectable within the limits of the 
polyacrylamide gel, however, only three of these sites were cleaved by the endonuclease. The 
three cleaved CU dinucleotides are present in single-stranded domains or stem-loop 
junctions, whereas the two uncleaved CU dinucleotides are localized within double-stranded 
domains. Furthermore, the detectable CU dinucleotide (1755 CU) within the 1705-1792 CRD 
RNA is double-stranded and is not cleaved by the endonuclease. However, upon generation
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of a single-stranded CU dinueleotide within the 1705-1792 CRD RNA, there was slight 
eleavage at this site (1741 CU within the CP-22 CRD mutant).
The endonuclease was also found to be capable of cleaving single-stranded UU, CC, 
AA, and UC dinucleotides, although the endonuclease does not seem to be specific towards 
these dinueleotides. There are two UU dinueleotides within the WT 1705-1792 CRD RNA: a 
single-stranded 1750 UU dinucleotide and a double-stranded 1756 UU. The endonuclease, 
however, was only capable of cleaving the single-stranded 1750 UU. Additional evidence for 
the ability of the endonuclease to cleave single-stranded UU dinueleotides included the 
eleavage of the three single-stranded dinueleotides: 4UU, 5UU, and 9UU and the absence of 
cleavage at dinucleotide 25 UU in the double-stranded region within the 3018-3159 (3-globin 
RNA. The endonuclease, however, appears to be non-specific to UU dinueleotides as 
indicated by the following evidence. The new UU dinueleotides within the CP-lOU (1751 
UU and 1752 UU) and CP-24 (1751 UU) present within single-stranded or stem-loop 
junctions were not cleaved by the mammalian endonuclease. Therefore, the cleavage of the 
1750 UU within the 1705-1792 CRD RNA maybe attributed to the proximity of the 1750 UU 
dinueleotide to the strongly cleaved 1751 UA site and to the 1747 UA eleavage site.
The non-specificity of the endonuclease towards CC dinueleotides is confirmed by 
the following evidence. The endonuclease was capable of cleaving two of the six detectable 
CC dinueleotides within the 1705-1792 CRD RNA. In addition, there was no eleavage at any 
of the CC dinueleotides present within the 3018-3159 [3-globin RNA. The eleavage of the 
two CC dinueleotides within the 1705-1792 CRD RNA maybe attributed to the proximity of 
the CC residues to the 1742 CA eleavage site and to the orientation of the CC dinueleotides 
within the tertiary structure. Such potential orientation may allow the CC dinueleotides to
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become more accessible for endonucleolytic cleavage. This finding is in agreement with the 
cleavage of the same CC residues within the CP-22 CRD mutant. The intense eleavage at the 
neighboring 1742 UA dinueleotide might have led to the increase in cleavage intensity at 
both CC dinueleotides: 1739 CC and 1740 CC.
The weak eleavage of the 1726 AA dinueleotide within the CP-19A CRD mutant and 
the somewhat stronger cleavage at the 1722 AA dinueleotide within the CP-22 CRD mutant 
is most likely a non-specific cleavage as indicated by the following evidence. There are 
thirteen AA dinueleotides within the 1705-1792 CRD region and none were cleaved by the 
endonuclease. In addition, there are four detectable AA dinueleotides in the 3018-3159 |3- 
globin RNA and none were eleaved by the endonuclease. Further eonfirmation of the non­
specificity of the endonuclease towards AA dinueleotides includes the absence of cleavage at 
the new AA sites at positions 1727 within the CP-19A and 1756 AA within the CP-22 CRD 
mutants.
The UC dinueleotide is not a preferred site for cleavage by the endonuclease. The 
eleavage of the single-stranded 10 UC dinueleotide within the 3018-3159 P-globin RNA is a 
non-specific cleavage and is most likely due to its proximity to the 1 - 1 2  nts region of the P- 
globin RNA, which contains several endonucleolytic cleavage sites. Evidence for the non­
specificity of the endonuclease towards UC dinueleotides includes the absence of cleavage at 
the remaining UC dinueleotides detectable within the limits of the gel (double-stranded 26 
UC and single-stranded 38 UC) and the lack of cleavage at the 1753 UC dinueleotide within 
the 1705-1792 CRD region.
In summary, the results indicate that the endonuclease is sequence-specific towards 
single-stranded and double-stranded UA, CA, UG dinueleotides and only single-stranded CU
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dinueleotides. The enzyme appears to be more specific towards UA dinueleotides compared 
to CA and UG dinueleotides as indicated by the following evidence. The new UA 
dinueleotide at position 1727 within the CP-19U CRD mutant was cleaved with more 
intensity than the wild-type 1727 CA. Furthermore, there was a deerease in cleavage at the 
1751 position upon mutating the UA dinueleotide into a UG dinueleotide (CP-IOG). The 
preference of the endonuclease towards UA dinueleotides can further be confirmed by 
running a time-point experiment where the substrate cleavage sites are analyzed at various 
time intervals. The cleavage sites generated at the earlier time-points indicate that the 
endonuclease has more affinity towards cleaving these dinueleotides than those observed at 
the later time-points. This experiment may also give insights on the preference of the 
endonuclease towards cleaving single-stranded or double-stranded dinueleotides. Further 
evidence of the sequence and structure specificity of this endonuclease to RNAs maybe 
obtained by running the polyacrylamide gel containing the CRD and P-globin transcripts at 
different time points. This would allow the resolution and identification of all cleavage sites 
within the RNA, therefore, providing stronger evidence for the endonuclease cleavage 
specificity. Lastly, incubating the endonuclease with different RNA substrates can potentially 
provide conclusive information regarding the sequence and structure specificity of the 
endonuclease to RNAs. The RNA substrates chosen, however, must be non-dynamic in order 
to confirm the specificity of the endonuclease towards double-stranded dinueleotides.
The results also indieate that the preferred dinueleotides for cleavage are not part of a 
consensus sequence as the endonuclease seems to cleave at each UA, CA, UG and single­
stranded CU dinueleotides. This cleavage property is different from that of PMR-1, which 
preferentially cleaves single-stranded UG dinueleotides only when present within the
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ApyrUGA consensus element (Hanson and Schoenberg, 2001). In addition, the finding that 
the endonuclease is also capable of cleaving other dinueleotides in a non-sequenee specific 
manner, indicates that the endonuclease is not a restriction enzyme. Such a property is similar 
to that of PMR-1, which is not thought of as a restriction enzyme in that other nucleotides 
than the consensus element can also be cleaved (Chernokalskaya et al., 1997).
It is important to point out that the cleavage specificity of the novel endonuclease 
under study, which was isolated from rat, was determined using human c-myc CRD RNA as 
a substrate. If this endonuclease is challenged with rat c-myc nts 1705-1792 CRD RNA, the 
cleavage specificity of the endonuclease would likely remain the same. Based on the 
determined cleavage specificity of the endonuclease, it would likely cleave at the following 
dinueleotides: 1707 CA, 1715 UG, 1720 UG, 1727 CA, 1742 CA, 1747 UA, 1751 UA, 1755 
CU, 1757 CA, 1766 CA, 1773 UA, 1775 CA, 1779 CU, 1780 UG, and 1788 CA (Figure 
3.11).
The cleavage at the fourteen sites of the 1705-1792 c-myc CRD and at the twenty-two 
sites of 3018-3159 P-globin RNA by the enzyme, in vitro, may not necessarily occur in vivo. 
Inside the cell, auxiliary factors such as the CRD-BP is present and binds to the 1705-1792 
CRD region, which potentially can cause an alteration in the secondary structure of the CRD 
RNA. The binding of the CRD-BP may also lead to an inhibition of endonucleolytic cleavage 
at certain sites within the 1705-1792 CRD. In particular, this effect maybe prominent near the 
1763-1777 CRD region, which is thought to be important for CRD-BP binding (Coulis et al., 
2000). It is currently unknown whether all five polypeptides comprising the mammalian 
endonuclease are important for endonucleolytic cleavage of c-myc in vivo. The absence of 
one or more polypeptides in vivo may generate different cleavage sites than the ones
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observed in vitro. In addition, the divalent cations in the cell may cause the c-myc and P- 
globin mRNAs to form tertiary structures, thereby, altering the accessibility of the 
dinueleotides for endonucleolytic cleavage. In addition, the sequence and structure cleavage 
specificity of the endonuclease to the 1705-1792 CRD and 3018-3159 P-globin RNAs maybe 
different in vivo due to the presence of auxiliary factors. This is thought to occur with the 
RNase III and Dicer enzymes, which show little sequence-specificity in vitro, but are thought 
to be sequence-specific in vivo (Condon and Putzer, 2002; Doi et al., 2003; Fortin et al., 
2002).
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Figure 3.11. The potential cleavages sites that are likely to be generated by the novel 
mammalian endonuclease upon incubation with rat c-myc nts 1705-1792 CRD RNA.
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Chapter 4 
General Discussion
Post-transcriptional regulation has recently emerged as a major control point of gene
expression in many organisms (Brewer, 2002; Dodson and Shapiro, 2002). One mode of
mRNA decay is via the deadenylation-independent pathway, which is thought to involve the
degradation of mRNAs by endoribonucleases, followed by exonucleolytic degradation
(Schoenberg and Cunningham, 1999). In mammals, however, only few endonucleases that
degrade mRNAs are known. Several mRNA decay intermediates have been described,
however, the responsible endonucleases remain unknown (Dodson and Shapiro, 2002). The
importance of controlling gene expression at the post-transcriptional level, underseores the
need to understand and characterize the implicated endonucleases.
A comparison between the novel mammalian endonuclease with known vertebrate 
endoribonucleases
The RNA cleavage specificity of the novel endoribonuclease is different from that of 
the three other endonucleases responsible for c-myc mRNA cleavage in vitro: the RasGap- 
associated G3BP, the -65 kDa RNase E-like endonuclease, and the -39  kDa endonuclease. 
The RasGap-G3BP endonuclease (52 kDa) prefers to cleave only single-stranded CA 
dinucleotides within the 3’UTR of c-myc mRNA (Barnes et al., 2002; Tourriere et al., 2001). 
This is in eontrast to the mammalian endonuclease under study, which preferentially cleaves, 
among other dinucleotides, both single-stranded and double-stranded CA dinucleotides. It 
also appears that the cleavage specificity of the mammalian endonuclease is independent of 
consensus elements in that any region within the c-myc mRNA, containing CA dinucleotides, 
is a potential target for the mammalian endonuclease. Furthermore, the mammalian 
endonuclease has different cleavage properties in comparison with the -65 kDa RNase E-like
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endonuclease. The dinueleotides cleaved by the mammalian endonuclease do not appear to 
be part of a consensus sequence, in contrast to the -65 kDa RNase E-like endonuclease. The 
RNase E-like endonuclease preferentially cleaves only within the 5 ’AUUUA 3’ motif, 
present in the 3’UTR of c-myc mRNA (Wennborg et al., 1995). The -39  kDa endonuclease 
cleaves predominantly in the A-rich 1726-1736 CRD region of c-myc mRNA, sparing other 
A-rich regions (Lee et al., 1998b). This seems to indicate that the -39 kDa endonuclease is 
substrate-specific and nucleotide cleavage may depend on the presence of consensus 
elements. Overall, the distinct cleavage sites generated by the novel mammalian 
endonuclease, indicates that the enzyme maybe part of a redundant pathway for the control of 
c-myc gene expression in cells. The alternative pathways would ensure steady-state levels of 
the essential growth-regulator gene, c-myc, in the event of inactivation of one pathway.
The novel mammalian endonuclease also exhibits different cleavage properties than those 
of endonucleases that have been purified from E.coli and yeast. Both bacterial RNase E and 
RNase G cleave only single-stranded regions within RNAs. In addition, these two 
endonucleases prefer to cleave 5’ to AU dinucleotides upstream of stem-loops (Coburn and 
Maekie, 1999; Waehi et al., 1999). The cleavage properties of the novel mammalian 
endonuclease are also different from that of bacterial RNase P, MazF, and PemK. All of 
these endonucleases are thought to cleave their target dinucleotides only when present within 
a consensus element. Furthermore, the mammalian endonuclease has different cleavage 
properties than the bacterial RNase III and yeast Rntlp. Both of these endonucleases cleave 
only double-stranded RNAs and the R ntlp endonuclease seems to cleave regions near 
consensus elements (Lamontagne and Elela, 2004).
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In addition, the cleavage specificity of the mammalian endonuclease is distinct in 
comparison with the specificity of all the vertebrate endonucleases mentioned in Table 1.3. 
The majority of these endonucleases cleave their target sequence only when present within a 
consensus element and/or when present in either single-stranded or double-stranded domains, 
but not both. Furthermore, none of the endonucleases mentioned in Table 1.3 have a 
preference for cleavage of UA, CA, UG, and CU dinucleotides. PMR-1 relies on consensus 
elements (ApyrUGA) for RNA cleavage and it degrades its RNA substrates (albumin and 
vitellogenin) only in the 3’ UTR (Cunningham et al., 2001). Furthermore, PMR-1 prefers to 
cleave UG dinucleotides only when present in single-stranded domains within the consensus 
element (Bremer et al., 2003; Hanson and Schoenberg, 2004). The polysomal endonuclease 
that was found to cleave P-globin mRNA is also capable of cleaving UG dinucleotides 
(Stevens et al., 2002). However, this cleavage occurs only when the dinucleotides are present 
within single-stranded domains (Stevens et al., 2002). RNase U preferentially cleaves UA 
and UU dinucleotides, only when present within single-stranded domains (Hua et al., 1993). 
This is different from the mammalian endonuclease, which is capable of cleaving UA 
dinucleotides in both single-stranded and double-stranded domains and has no sequence- 
specificity to UU dinucleotides. Dicer has little sequence specificity in vitro and prefers to 
cleave its target sequences only when present in double-stranded domains (Doi et al., 2003; 
Fortin et al., 2002). This in contrast to the novel mammalian endonuclease which is also 
capable of cleaving double-stranded RNA, but with sequence specificity. Lastly, in contrast 
to the mammalian endonuclease, ErEN appears to be a substrate-specific endonuclease as it 
preferentially cleaves the a-globin mRNA only at the 63 CU dinucleotide position 
(strandedness of this CU dinucleotide is unknown) (Rodgers et al., 2002). The remaining
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endonucleases mentioned in Table 1.3 are substrate-specifie as they cleave their target 
sequence only when present within or near eonsensus elements.
Evidence that the novel endonuclease is different from RNase A
Upon incubation of the CP-22 CRD structure mutant with the endonuelease, cleavage was 
observed at the double-stranded 1755 UA dinucleotide, the single-stranded 1722 AA 
dinucleotide, and the single-stranded 1741 CU dinucleotide. RNase A was not capable of 
cleaving at any of these dinucleotides. Upon incubation of the CP-24 CRD structure mutant 
by the endonuelease, eleavage occurred at the 1752 UA dinucleotide. However, there was no 
cleavage at this site by RNase A. Furthermore, cleavage at the 1747 UA dinucleotide was 
more pronounced than the cleavage generated by RNase A at this site. Other evidence 
indicating that the two enzymes are distinet include the differential cleavage generated upon 
incubation of a -  170 nt region spanning the MDR-1 (multi-drug resistance) RNA with the 
mammalian endonuclease and RNase A (unpublished observation). The results clearly show 
that there are several bands that are present in the RNase A lane, but not in the endonuclease 
lane or vice versa (data not shown). In addition, RNase A is known to generate 5’ fragments, 
each with a 3’phospate terminal (Mishra, 2002), whereas the mammalian endonuclease has 
been shown to generate a 5’ fragment with a 3’ hydroxyl terminal (Bergstrom et al., in press). 
Lastly, RNase A is known to exist as a dimer in vivo (Mishra, 2002), whereas the mammalian 
endonuclease is thought to be composed of five polypeptides in the cell. One of the five 
polypeptides has a size of ~ 35 kDa and has been tentatively identified to be a SNAP (S- 
nitroso-N-acetyl-D,L-penicillamine) receptor protein.
The novel mammalian endonuclease maybe part of the RNase A family, due to the 
slight similarity in the cleavage sites generated between the two enzymes. Two members of
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the RNase A family: onconase (11.2 kDa) and bovine-seminal RNase (BS-RNase) (27 kDa) 
(Bracale et al., 2003; Lee and Raines, 2003) generate similar cleavage sites to RNase A (Kim 
et al., 1995; Leland and Raines, 2001; Lei and et al., 1998). The major difference between 
onconase and RNase A (~ 30% homology) is attributed to the additional disulfide bond 
present at the C-terminus of onconase (Lee and Raines, 2003). Furthermore, the three main 
catalytic sites of RNase A: His^°, His^^, and Lys^^ are conserved in onconase (Leland and 
Raines, 2001; Leland et al., 1998). The other RNase A family member, BS-RNase, contains 
80% homology with RNase A and has an identical active site to that corresponding to RNase 
A (Ereole et al., 2003). In addition to cleaving single-stranded RNA, BS-RNase was also 
found to cleave double-stranded RNA (sequences cleaved not determined) (Schein et al., 
1990), indicating the possibility that the BS-RNase may have a similar mechanism of action 
as that of the mammalian endonuclease under study. However, to confirm that the 
mammalian endonuclease is indeed a member of the RNase A family, all five polypeptides 
must first be identified to determine if there is protein sequence homology with RNase A and 
the possible existence of an identical active site to that of RNase A.
Despite of the aforementioned differences between the novel mammalian endonuclease 
and RNase A, the two enzymes possess similar cleavage specificity. However, this cleavage 
specificity is likely to be different in vivo. The potential difference in cleavage specificity 
between the two enzymes, in vivo, may occur to the different compartmentalization of the 
two enzymes, the different putative protein-protein interactions, and/or whether or not they 
are phosphorylation-dependent.
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Significance of the mammalian endonuclease in vivo and future experiments
The mammalian endonuclease maybe the enzyme responsible for the endonucleolytic 
cleavage of the c-myc CRD in the liver (Hanson and Schoenberg, 2001; Pistol et al., 1996). 
This endonucleolytic cleavage is potentially the rate-limiting step in the deadenylation- 
independent pathway of c-myc mRNA eleavage in vivo. The endonucleolytic fragments 
generated by the enzyme may then be subjected to exonucleolytic degradation by the 5’ to 3’ 
and/or the 3’ to 5’ exonueleases. Degradation of the 5 ’ fragment by 3’ to 5’ exonucleases 
requires the presence of a 3’ hydroxyl on the 5’ cleavage fragment (Mishra, 2002). The 
mammalian endonuclease is thought to generate cleavage fragments containing 3’ hydroxyl 
groups (Bergstrom et al., in press), therefore, generating proper substrates for 3' to 5’ 
exonucleases. In addition, the mammalian endonuclease may exist within a multi-protein 
complex, similar to the bacterial degradosome. The bacterial degradosome consists of the 
endonuclease, RNase E, a 3’ to 5’ exonuclease (PNPase), and several other ATP-requiring 
enzymes (Coburn and Maekie, 1999).
It is also important to note that the experiments in this project were performed in 
vitro. The in vitro findings maybe different from those determined in vivo due to the presence 
of auxiliary proteins and divalent cations in the cellular environment. Future experiments 
must then be undertaken in vivo to confirm the secondary structure of the 1705-1792 c-myc 
CRD region and the cleavage specificity of the endoribonuclease to this region. Two 
potential experiments could be performed to determine the secondary structure of the 1705- 
1792 c-myc CRD in vivo. The first experiment would involve isolating total RNA from K562 
cell-lines (abundant in c-myc mRNA), followed by incubation with the same RNase probes 
used in this project. Cleavage fragments could then be detected using primer extension
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(Ehresmann et al., 1987). Several primers eorresponding to the 1705-1792 region can be used 
to confirm the secondary structure of the 1705-1792 CRD region in vivo. The other 
experiment would involve treating the K562 cell-lines with chemical probes such as 
dimethylsulfate (DMS) and 1 -cyclohexyl-3-(2-morpholinoethyl) carodiimide metho-p- 
toluene sulfonate (CMCT) which modify single-stranded A,C and U,G residues, respectively 
(Ehresmann et al., 1987). Total RNA would then isolated from the cell-lines, followed by 
primer extension.
In order to determine the sequence and structure cleavage specificity of the 
mammalian endoribonuclease to the 1705-1792 c-myc CRD region in vivo, the mammalian 
endonuclease must first be cloned. The cDNA corresponding to the endonuclease could be 
ligated to an expression vector and transfected into K562 leukemic cell-lines. Any stable 
degradation products generated by the endonuclease could then be detected using sensitive 
detection methods such as ligation-mediated PCR (LM-PCR) (Hanson and Schoenberg, 
2004; Lee et al., 1998b) and 81 nuclease mapping (Stevens et al., 2002).
Therapeutic implication of the novel mammalian endonuclease
In theory, the novel mammalian endonuclease may have a potential therapeutic 
application against different types of diseases such as cancer and viral infections. Such 
application exploits the specificity of the endonuelease to UA, CA, UG, and single-stranded 
CU residues, which are likely to be abundant in any RNA substrate. The endonuclease maybe 
used directly to degrade mRNAs present in cancer cells or viral RNAs present in virus- 
infected cells, thereby inhibiting protein synthesis. The degradation of mRNA by the 
endonuclease might also lead to apoptosis as has been shown with the two members of the 
RNase A family, which were used in cancer therapeutics. Both onconase and BS-RNase are
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capable of promoting cytotoxic effects in cancer cells (Bracale et al., 2002; Haigis and 
Raines, 2003). The cytotoxic pathway involves three steps: binding to cell-surfaee, 
endocytosis, and cleavage of the RNA target, leading to inhibition of protein synthesis and 
apoptosis (Bracale et al., 2002; Haigis and Raines, 2003). The primary target for onconase, 
however, is thought to be tRNA (Irie et al., 1998), whereas the primary target for BS-RNase 
is thought to be rRNA (Bracale et al., 2002). The limited number of RNA targets cleaved by 
the two RNase A family members, point to the potential versatility and hence the potency of 
the mammalian endonuelease in targeting any type of RNA, including mRNA.
The mammalian endonuelease may also be used in conjunction with traditional 
chemotherapeutic drugs to promote death of chemoresistant cells. This type of therapy has 
been successfully accomplished utilizing BS-RNase, against human neuroblastoma cancer 
cell-lines, which contain the multi-drug resistance (MDR) phenotype (Cinatl et al., 1999). 
This treatment led to the induction of apoptosis in these cell-lines and to the inhibition of 
cellular growth (Cinatl et ah, 1999). The mammalian endonuclease may also be used to target 
cells infected with viral RNAs. Such application would potentially be similar to that of 
onconase, that was utilized to target human leukemia cells infected with HIV-1 (Saxena et 
al., 2002). Such treatment led to the degradation of viral RNAs and eventually led to a 
decrease in HIV-1 replication (Saxena et ah, 2002).
Concluding remarks
This work has revealed important information about the secondary structures of the 
1705-1792 c-myc CRD RNA and the 3018-3159 (3-globin RNA in vitro. Both structures are 
dynamic in that they can alternate between an open and a double-stranded structure. The 
elucidated structures may provide insight into the secondary structures in vivo. Knowledge
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of the secondary structures has also allowed for the determination of the structure specificity 
of the novel mammalian endoribonuclease in vitro. Using a series of CRD mutants as 
substrates, it was determined that the mammalian endonuclease prefers to cleave UA, CA, 
and UG dinucleotides, regardless of strandedness, while only single-stranded CU 
dinucleotides are preferentially cleaved. This finding was also confirmed using the 3018- 
3159 (3-globin RNA as a substrate.
The obtained results indicate that the novel mammalian endonuclease is non-substrate 
specific as other RNAs such as (3-globin and MDR-1 were also degraded by the novel 
mammalian endonuclease, in-vitro. In addition, based on the cleavage specificity of the 
endonuclease, other RNA classes such as rRNA and tRNA are also potential targets by the 
novel endonuclease. Such cleavage specificity appears to be similar to that of bacterial 
RNases, which are not dedicated to cleave specific mRNAs or particular RNA classes 
(Deutscher, 2006). Rather, it was found that the specificity of the endonuclease and the 
accessibility of the substrate are the sole determinants of whether or not a particular RNA 
will be targeted (Deutscher, 2006).
Overall, the distinct sequence and structure cleavage specificity of the mammalian 
endonuclease indicates that it is indeed a novel endonuclease, different from other currently 
known mammalian endonucleases. The research described here has added significant 
information to our limited knowledge on RNA cleavage specificity by the recently identified 
novel mammalian endoribonuclease.
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The Obtained Sequences of the CRD Mutants
1 7 1 0  1 7 2 0  1 7 3 0  1 7 4 0  1 7 5 0  1 7 6 0  1 7 7 0
A  B C
C P - 2 GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCAA GGTAG TA TTCC TTAAAAAAGCCACAG
C P - I O G  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCAA GGTAG TTGTCC TTAAAAAAGCCACAG
C P - I O C  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCAA GGTAG TTGTCC TTAAAAAAGCCACAG
C P - 3  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCAA GGTAG TTATCC TATAAAAAGCCACAG
C P - 2 4  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCAA GGTAG TTTACC TTAAAAAAGCCACAG
C P - l O U  GGATCC A TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCA A G G TA G TTTTCC TTAAAAAAGCCACAG
C P - 1 5  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA AACATGAAAAGGCCC CCAA GGTAG TTATCC TTAAAAAAGCCACAG
C P - 1 9 A  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA AAAATGAAAAGGCCC CCAA GGTAG TTATCC TTAAAAAAGCCACAG
C P - 1 9 G  GG ATCCATTTAG GTG ACACTATAGACCAGA TCCCGGAGTTGGAAA ACAATGAAAAGGCCC CCAA GGTAG TTATCC TTAAAAAAGCCACAG
C P - 1 9 U  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA ATAATGAAAAGGCCC CCAA GGTAG TTATCC TTAAAAAAGCCACAG
C P - 1 3  GGATCCA TTTA G G TG  ACACTATAGACCAGA TCCCGGAGTTGGAAA A C A A -G TA A A G G C C C  CCAA GGTAG TTATCC TTAAAAAAGCCACAG
C P - 2 2  GGATCCA TTTA G G TG  ACACTATAGACCAGA T C C A G - AGTTGGAAA ACAATGAAAAGGCCC CCTA G G TA G TTA TCC TAAAAAAAGCCACAG
1 7 8 0  1 7 9 0
C D
C P - 2  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - I O G  -A T A C A T C C T G T C C G  TCCAAGCGAATTC
C P - I O C  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 3  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 2 4  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - l O U  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 1 5  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 1 9 A  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 1 9 G  C ATACA TCCTGTCCG TCCAAGCGAATTC
C P - 1 9 U  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 1 3  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
C P - 2 2  C A TA CA TCCTG TCCG  TCCAAGCGAATTC
Figure A .I. Alignment of the 12 sequenced CRD mutants using the BCM Search Launcher (Smith et al., 1996). Region A (bold) represent the Bam Rl 
Restriction site, region B represents the SP-6 RNA polymerase promoter (underlined), region C represents the 1705-1792 CRD sequence, while 
Region D (bold) represents the EcoBl restriction site. Numbering indicates the CRD regions.
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